The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2011

A NOVEL FUNCTION FOR AURORA B KINASE IN THE
REGULATION OF P53 BY PHOSPHORYLATION
chris p. gully

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Biochemistry Commons, Cancer Biology Commons, Cell Biology Commons, and the
Molecular Biology Commons

Recommended Citation
gully, chris p., "A NOVEL FUNCTION FOR AURORA B KINASE IN THE REGULATION OF P53 BY
PHOSPHORYLATION" (2011). The University of Texas MD Anderson Cancer Center UTHealth Graduate
School of Biomedical Sciences Dissertations and Theses (Open Access). 132.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/132

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

A NOVEL FUNCTION FOR AURORA B KINASE IN THE
REGULATION OF P53 BY PHOSPHORYLATION
by
Christopher Patrick Gully, B.S., M.S.

APPROVED:
______________________________
Mong-Hong Lee, Ph.D.
Supervisory Professor
______________________________
Min Gyu Lee, Ph.D.
______________________________
Randy J. Legerski, Ph.D.
______________________________
Hui-Kuan Lin, Ph.D.
______________________________
Sai-Ching Yeung, M.D., Ph.D.

APPROVED:

____________________________
George M. Stancel, Ph.D.
Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

A NOVEL FUNCTION FOR AURORA B KINASE IN THE
REGULATION OF P53 BY PHOSPHORYLATION

A

DISSERTATION

Presented to the Faculty of
The University of Texas
Health Science Center at Houston
and
The University of Texas
M. D. Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
DOCTOR OF PHILOSOPHY

by
Christopher Patrick Gully, B.S., M.S.
Houston, Texas
May 2011

Dedication

To my wife and best friend Shirl,

for all her patience and support.

I couldn’t have done this without you.

iii

Acknowledgements
It is my sincerest wish to convey my utmost gratitude to the many people
who have aided me throughout my Ph.D. studies. Without their encouragement,
support and advice, the completion of this dissertation would not have been
possible.

I would like to thank in particular, my mentor, Dr. Mong-Hong Lee for his
guidance, wisdom, expertise and kindness over the course of my career in
graduate school. He has been a model of integrity and honesty and brought to
me a great enthusiasm for success in furthering scientific advances. He is also a
kindred spirit in his respect for all life and the pursuit of the highest ethical
standards to which we must all aspire in scientific research. His devotion has
given me the knowledge and desire to succeed and I hope I can repay this debt
by being a committed scientist who makes meaningful contributions to our field. I
would also especially like to thank Dr. Sai-Ching “Jim’ Yeung for our many
productive, thoughtful discussions and his guidance on my academic path. Dr.
Yeung’s work ethic and ability to incorporate clinical vision in our work serves as
an inspiration for many of us in our lab. My interaction with him has been at all
times fruitful and informative. I appreciate all he has done for me and our group
at MD Anderson. Many thanks also go to my other committee members Dr. HuiKuan Lin, Dr. Randy Legerski, Dr. Min Gyu Lee, Dr. Dos Sarbassov, Dr. Pierre
McCrae and Dr. Lalitha Nagajaran for their time and effort in giving me thoughtful

iv

critiques, thought provoking discussion and a rigorous candidacy exam. My
gratitude also goes to Dr. Ralph Arlinghaus for allowing me to rotate in his lab.

I truly appreciate all my colleagues including Guermarie Velazquez-Torres
for her dedication to our lab and all of her efforts in making it a place where we
can all work efficiently and effectively, Dr. Jian Chen for his guidance, training
and unwavering willingness to serve as a sounding board for scientific ideas and
Dr. Enrique Fuentes-Mattei for his expertise and calm under-pressure confidence
through stressful times. I would also like to thank many other colleagues for their
support and expertise over the course of my project: Edward Wang, Colin
Carlock, Ji-Hyun Shin, James Yeung, Daniel Rothenberg, Hyun-Ho Choi, ChunHui Su, Sergei Guma, Hank Adams, Dr. Jerry Teng, Fanmao Zhang and Ben
Chou.

For all of the material support I have received during my time at MD
Anderson, I would like to thank the people who provided reagents, plasmids,
antibodies or direct training, Elsa Flores, Randy Legerski, Jill Schumacher,
Wendy Schober, Gordon Mills, Subrata Sen, Hiroshi Katayama, Zenbo Han, Bert
Vogelstein, Cheng-Ming Chian, Hui-Kuan Lin, Zeev Ronai, Gigi Lozano, Jeffrey
Wahl, Edward Yeh and Jiangdong Chen.

My most humble and sincere appreciation also goes to the forty laboratory
mice who gave their lives in the interest of human health. It is my hope that their
sacrifice will serve to further the field of cancer research and I will do my best to
ensure that the data collected will be used to its fullest potential to do so.
v

Last, I would like to thank my my wife Shirl for her support, patience and
caring over the past four years. She has served as my inspiration and greatest
advocate. She shared my successes and setbacks along the way and without
her, the completion of my Ph.D. would not have been possible.

vi

Abstract
The mitotic kinase Aurora B plays a pivotal role in mitosis and cytokinesis
and governs the spindle assembly checkpoint which ensures correct
chromosome segregation and normal progression through mitosis. Aurora B is
overexpressed in breast and other cancers and may be an important molecular
target for chemotherapy. Tumor suppressor p53 is the guardian of the genome
and an important negative regulator of the cell cycle. Previously, it was unknown
whether Aurora B and p53 had mutual regulation during the cell cycle. A small
molecule specific inhibitor of Aurora B, AZD1152, gave us an indication that
Aurora B negatively impacted p53 during interphase and mitosis. Here, we show
the antineoplastic activity of AZD1152 in six human breast cancer cell lines, three
of which overexpress HER2. AZD1152 specifically inhibited Aurora B kinase
activity, thereby causing mitotic catastrophe, polyploidy and apoptosis, which in
turn led to apoptotic death. Further, AZD1152 administration efficiently
suppressed tumor growth in orthotopic and metastatic breast cancer cell
xenograft models. Notably, it was found that the protein level of Aurora B kinase
declined after inhibition of Aurora B kinase activity. Investigation of the
underlying mechanism suggested that AZD1152 accelerated the protein turnover
of Aurora B by enhancing its ubiquitination.
As a consequence of inhibition of Aurora B, p53 levels were increased in
tissue culture and murine models. This hinted at a possible direct interaction
between p53 and Aurora B. Indeed, it was found that p53 and Aurora B exist in
complex and interact directly during interphase and at the centromere in mitosis.
vii

Further, Aurora B was shown to phosphorylate p53 at several serine/threonine
residues in the DNA binding domain and these events caused downregulation of
p53 levels via ubiquitination mediated by Mdm2. Importantly, phosphorylation of
threonine 211 was shown to reduce p53’s transcriptional activity while other
phosphorylation sites did not. On a functional level, Aurora B was shown to
reduce p53’s capacity to mediate apoptosis in response to the DNA damaging
agent, cisplatin. These results define a novel mechanism for p53 inactivation by
Aurora B and imply that oncogenic hyperactivation or overexpression of Aurora B
may compromise p53’s tumor suppressor function.
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Chapter 1. Introduction
1.1 The Aurora Kinase Family
The Aurora family of mitotic kinases are a group of evolutionarily
conserved serine/threonine kinases (Vas and Clarke, 2008) which share
approximately 70% homology in their kinase domains (Katayama et al., 2003;
Tao et al., 2008; Yang et al., 2007) (Figure 1). The Auroras are so named
because of the discovery of Aurora A in Drosophila, a mutation of which caused
aberrations at the spindle poles mimicking a likeness of the aurora borealis
(Glover et al., 1995). The Auroras are essential in cell cycle control and are
crucial regulators from mitotic entry to cytokinesis ensuring that daughter cells
receive the correct number of chromosomes (Carmena et al., 2009; Ducat and
Zheng, 2004; Fu et al., 2007; Kaitna et al., 2002; Katayama et al., 2003; Lens
and Medema, 2003; Petersen and Hagan, 2003; Satinover et al., 2006;
Vagnarelli and Earnshaw, 2004). Mammals have three Aurora family members,
A, B and C, while Drosophila, Xenopus and C. elegans have two. The budding
yeast, S. cerevisiea, has only one Aurora, Ipl1P (Sugiyama et al., 2002; Vas and
Clarke, 2008). Aurora kinases in humans range from 309 to 403 amino acids
with Aurora B at the medium length of 343. Each of the kinases contain an Nterminal regulatory domain, a catalytic domain and a variable C-terminal domain.
The genes encoding the Auroras reside on 20q13.2, 17p13.1 and 10q13 for A, B
and C respectively (Bernard et al., 1998; Bischoff et al., 1998; Kimura et al.,
1998).
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Although the Aurora kinases are expressed at maximum levels during
mitosis, the two main players, Aurora A and Aurora B, have distinct subcellular
localizations and serve differing functions during mitosis. All Aurora kinases
have been observed to be overexpressed or amplified in human cancer (Fu et
al., 2007; Keen and Taylor, 2004; Nadler et al., 2008) and contribute to
tumorigenesis via their link to invasive disease and their ability to cause genomic
instability (Bischoff et al., 1998; Carmena and Earnshaw, 2003; Ducat and
Zheng, 2004). Auroras A and B have also been found to be overexpressed in
many cancer cell lines (Katayama et al., 1999; Sasai et al., 2004; Tatsuka et al.,
1998; Zhou et al., 1998) and their inhibition has shown tumor regression in
xenografted tumors (Harrington et al., 2004).
Aurora A kinase resides primarily at the centrosomes and at the spindle
pole ends during mitosis and has functions in centrosome maturation, mitotic
entry and bipolarity of spindles (Adams et al., 2001; Carmena and Earnshaw,
2003; Nigg, 2001). The function of Aurora A depends upon its ability to bind
microtubules and its localization at the spindle poles where it phosphorylates and
activates CDC25B at serine 353, which leads to activation of Cyclin B/CDK1
(Cazales et al., 2005; Dutertre et al., 2004). Another well known substrate of
Aurora A is TPX2 which is a strong binding partner and activator of Aurora A
(Eyers and Maller, 2004). Aurora A also plays a role in the activation of PLK1
which further contributes to Cyclin B/CDK1 activation (Macurek et al., 2008; Seki
et al., 2008).

2

Auroras A and B are very similar to each other in their kinase domains and
their regulation is largely governed by localization and activation by binding
partners. Further, Auroras A and B share some substrates (Histone H3, INCENP
and Survivin (Fu et al., 2009; Hans et al., 2009)), which could become important
were these kinases to be overexpressed or mislocalized. Also, a point mutant of
Aurora A (G198N) displays localization similar to Aurora B, can partially restore
loss of Aurora B function and is known to exist in complex with other
Chromosome Passenger Complex (CPC) members (Fu et al., 2009; Hans et al.,
2009). Nevertheless, Auroras A and B have distinct mitotic functions.
Human Aurora B is also known as Aurora-1, AIRK2, ARK2, Aik2, STK-12
while mouse Aurora B is known as STK-1 and rat as AIM-1 (Sugiyama et al.,
2002). Aurora B is the enzymatically active member of the CPC (Carmena et al.,
2009) which resides at the inner centromere during early mitosis and relocates to
the spindle midzone during anaphase and telophase (Ruchaud et al., 2007;
Vader and Lens, 2008). The CPC is composed of Aurora B and its substrates,
INCENP, Survivin and Borealin (Carmena et al., 2009). Aurora B’s main
functions are to govern the correct attachment of spindle fibers during
chromosome alignment as well as govern the spindle assembly checkpoint
(SAC).
The third member of the Aurora kinase family in humans is Aurora C.
Very little is known about Aurora C except that it is very similar to Aurora B in
percent identity and function and is known to be a member of the CPC involved

3

in assembly of meiotic spindles during spermatogenesis (Carmena and
Earnshaw, 2003; Carmena et al., 2009).

4

Figure 1. Schematic representation of the domains of the three members
of the human Aurora kinase family.
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1.2 Aurora B Kinase Activation and the Chromosome Passenger Complex
In addition to Aurora B’s function as the major kinase that governs the
turnover of kinetochore-microtubule interactions and manages the spindle
assembly checkpoint, it also functions in chromatid cohesion, spindle stability
and cytokinesis (Ruchaud et al., 2007) and is therefore a multifunctional player
during mitotic progression.
Localization and activation of Aurora B requires the other CPC members
as binding partners and substrates (Adams et al., 2000; Gassmann et al., 2004;
Terada et al., 1998; Uren et al., 2000; Wheatley et al., 2001). (See Table 1 for a
complete list of Aurora B substrates.) A 1:1:1 complex can be formed by the
binding of the N-terminus of both INCENP and Borealin to the C-terminus of
Survivin. This complex is stable and is able to localize to the inner centromere
where Aurora B binds via the IN-Box of INCENP (Adams et al., 2000). The
binding of Aurora B to INCENP increases the basal kinase activity which allows
Aurora B to both autophosphorylate its T-loop and phosphorylate INCENP at a
TSS motif near the C-terminus (Bishop and Schumacher, 2002; Carmena et al.,
2009; Sessa et al., 2005). The phosphorylation of INCENP by Aurora B has
been shown to be necessary for full Aurora B activation (Kelly et al., 2007).

In addition to Aurora B’s kinase activity being necessary for its activation,
several other mitotic kinases are known to aid in Aurora B’s activation. Tousledlike kinase (TLK-1) was found to be a substrate activator of Aurora B (Han et al.,
2005) as well as Chk1 which phosphorylates Aurora B and increases its activity

6

(Zachos et al., 2007). Further, Mps1, yet another mitotic kinase that is required
for a proper spindle assembly checkpoint, controls spindle fiber-kinetochore
attachments by phosphorylating Borealin, which in-turn increases the activation
of Aurora B (Jelluma et al., 2008). And lastly, an integral part of the spindle
assembly checkpoint itself, kinase BubR1 resides at the kinetochore and acts as
a negative feedback regulator of Aurora B (Ditchfield et al., 2003; Hauf et al.,
2003; Lampson and Kapoor, 2005; Morrow et al., 2005).

In the opposite way that many mitotic kinases act to activate Aurora B,
there are phosphatases that act as negative regulators. Protein Phosphatase 1
(PP1) and PP2A both bind and inhibit Aurora B by dephosphorylation (Sugiyama
et al., 2002; Sun et al., 2008). During anaphase, plus-end microtubule binding
protein EB1 blocks Aurora B’s T-loop from dephosphorylation by PP2A (Sun et
al., 2008). It is through a delicate balance of phosphorylation and
dephosphorylation of Aurora B or its substrates, that the activation of Aurora B is
managed.

Another mechanism for the regulation of Aurora B comes from its
degradation by the E3 ligase, Anaphase Promoting Complex (APC) together with
its substrate recognition subunits Cdh1 and Cdc20. At the onset of anaphase
APC facilitates the ubiquitination of Aurora B which requires the A-Box and KEN
box found in the first 65 amino acids (Nguyen et al., 2005). Aurora B is then
rapidly degraded via the ubiquitin-proteasome pathway.
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Table 1. List of Aurora B Substrates

Substrate

Amino Acid

Reference

Histone H3

S10, S28

(Crosio et al., 2002; Goto et
al., 2002)

CENP-A

S7

(Zeitlin et al., 2001b)

GFAP

T7, S13, S38

(Kawajiri et al., 2003)

Desmin

S59

(Kawajiri et al., 2003)

INCENP

T893, S894, S895

(Bishop and Schumacher,
2002)

MgcRacGAP

S387, S410

(Minoshima et al., 2003)

REC-8

T625, S626

(Rogers et al., 2002)

Vimentin

S72

(Goto et al., 2003)

Survivin

T117

(Wheatley et al., 2004)

MCAK

S161, T162, S177, S196,
T229, S253

(Lan et al., 2004)

Hec1/Ndc80

Multiple N-term

(DeLuca et al., 2006)

Topoisomerase II
Tousled-like
kinase

(Morrison et al., 2002)
S634

(Han et al., 2005)
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1.3 Function of Aurora B Kinase
As discussed previously, Aurora B and the CPC have multiple roles to
play in mitosis and these can be separated into roughly two categories, a role at
the centromere during early mitosis (prophase-metaphase) and a role at the
midbody during late mitosis and cytokinesis (anaphase-telophase). Upon mitotic
entry, Aurora B and the CPC are localized at the chromosome arms and are
mainly apparent at the centromere (Beardmore et al., 2004). After metaphase
and with the onset of anaphase, Aurora B and the CPC relocate to the
midbody/spindle midzone.
During early mitosis, Aurora B as well as the CPC recruit many effector
proteins to the kinetochore and the inner centromere. Kinetochore proteins
recruited by the CPC include Bub1, BubR1, Mad1, Mad2, Mps1 and Cenp-E
(Ditchfield et al., 2003; Lens et al., 2003; Vigneron et al., 2004). Kinetochoremicrotubule interaction proteins include Cenp-E, Ndc80, Kn11, Mis12, Zwilch
MCAK, PLK1 and Dam1 (Andersson et al., 1989; Emanuele et al., 2008; Goto et
al., 2006; Lan et al., 2004; Ohi et al., 2004; Pouwels et al., 2007). Inner
centromere proteins recruited include MCAK, Sgo1 and Sgo2 (Goto et al., 2006;
Kawashima et al., 2007; Pouwels et al., 2007). It has been shown that if the
CPC does not function properly, syntelic and merotelic attachments (Cimini et al.,
2006; Ditchfield et al., 2003; Hauf et al., 2003) will result most likely due to
improper attachments failing to be resolved (Figure 2) (Lampson et al., 2004;
Tanaka et al., 2002). Phosphorylation of some of these proteins is thought to
destabilize incorrect attachments and facilitate correct reattachment. Likewise,
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both Aurora B and the CPC are found to be more abundant at incorrect
attachments (Knowlton et al., 2006). Some reports have also concluded that
Aurora B phosphorylation occurs less during metaphase than prophase
suggesting that at metaphase, some correct attachments already exist and do
not need to be released (Andrews et al., 2004; Lan et al., 2004; Zeitlin et al.,
2001a).

Although the actual function of Aurora B and the CPC with regard to how
they regulate correct spindle fiber attachments is unknown, one promising model
suggests that via phosphorylation, Aurora B continually destabilizes microtubulekinetochore interaction until a correct attachment results in tension pulling across
both kinetochores, which in-turn pulls Aurora B’s substrates away from its local
zone of influence (Tanaka et al., 2002). This would lead to stabilized
attachments and satisfaction of the spindle assembly checkpoint. Other studies
confirmed this by noting the levels of phosphorylated MCAK in correct versus
incorrect attachment scenarios and found that MCAK has reduced
phosphorylation when attachments were incorrect and no tension was present
(Andrews et al., 2004; Lan et al., 2004). Another study further confirmed this by
tethering Aurora B to the inner centromere and found that when tethered, Aurora
B could not fully disrupt interactions. Conversely, when Aurora B was linked to
the kinetochore, it could disrupt attachments and stable biorientation could not
occur (Liu et al., 2009). In addition to MCAK as an effector substrate of Aurora
B, Hec1/Ndc80, an important component of the microtubule binding KMN
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network, is known to be phosphorylated by Aurora B thereby decreasing the
affinity of Hec1 for microtubules (Cheeseman et al., 2006; DeLuca et al., 2006).

The spindle assembly checkpoint (SAC) is a mechanism that prevents the
completion of mitosis (anaphase onset) until all chromosomes have biorientation
and tension across their kinetochores. The yeast Aurora kinase Ip11 has been
shown to be required for SAC function when no tension is present (Biggins and
Murray, 2001; Pinsky et al., 2006). Also, as seen in vertebrates, by inhibition of
Aurora B with small molecule inhibitors, it was shown that Aurora B is necessary
for a proper SAC in response to taxol, a microtubule stabilizing agent (Kallio et
al., 2002).

As mentioned previously, after the onset of anaphase, Aurora B and the
CPC change localization to the midbody and carry out an entirely different
function in cytokinesis. This change of localization was found to be essential for
late mitotic events to progress (Carmena and Earnshaw, 2003; Ruchaud et al.,
2007; Vader and Lens, 2008; Vagnarelli and Earnshaw, 2004). Indeed the
position of the cleavage furrow is determined by a RhoA microtubule dependent
zone induced by Aurora B phosphorylation of the central spindlin complex
proteins MKLP1/ZENK and the GTPase activating protein 1 (MgcRacGAP)
(Bement et al., 2005; Minoshima et al., 2003; Mishima et al., 2002; Wadsworth,
2005).
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Figure 2. Overview of Kinetochore
Kinetochore-Microtubule
Microtubule Orientation Types. From
Top, Amphitelic,, correct attachment, microtubules connected to corresponding
kinetochores from each pole. Monotelic, microtubules from only one pole
connected to corresponding kinetochore. Syntelic, microtubules from one pole
connected to both kinetochores. Merotelic
Merotelic,, microtubules from both poles
connected to one kinetochore.
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1.4 Aurora B Kinase and its Role in Cancer
Although it has been well established that Aurora A is overexpressed in
many cancer types and is considered to be a high value target for new and
developing chemotherapy agents, Aurora B is not quite so well known as an
oncogene and the evidence for such a claim is still not conclusive. Despite this,
there are many reports that show that Aurora B is overexpressed in many cancer
types (Table 2) such as colorectal cancer (Katayama et al., 1999), oral cancers
(Qi et al., 2007), breast cancer (Tchatchou et al., 2007) and hepatocellular
carcinoma (Lin et al.).
It makes sense, however, that Aurora B could function as a classical
oncogene given its diverse roles in governing mitosis and handling of proper
genome fidelity such as spindle checkpoint function, cytokinesis and
chromosome segregation. Without Aurora B or with perturbation of Aurora B
levels, genomic fidelity could be altered in a way so as to create aneuploidy and
genomic instability.

One report found that when resected tumors from human patients were
analyzed by Western blotting, Northern blotting and in situ hybridization, Aurora
B overexpression or amplification correlated with colon cancer progression
(Katayama et al., 1999). Further, in colorectal cancer cell lines, increased levels
of Aurora B correlated to increased phosphorylation of Histone H3 and
aneuploidy (Ota et al., 2002). Aurora B levels were also found to be increased
along with anaplasia in thyroid carcinoma (Sorrentino et al., 2005).
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Aurora B has been shown to be effective in transformation phenotypes.
Murine embryo fibroblasts, in which Aurora B was overexpressed, were not only
shown to be transformed but significantly, they were able to form invasive tumors
in mice. Also, Aurora B overexpression was shown to enhance the tumorigenic
phenotype of Ras-V12 transformed cells (Kanda et al., 2005).

Clearly, Aurora B has been shown to contribute to tumorigenesis and
progression in several cancer and cell types, including, breast cancer. Aurora B
overexpression was not found to correlate to survival in human cases in contrast
to Aurora A (Nadler et al., 2008). Therefore, although there is some evidence
that Aurora B’s function as a classical oncogene seems apparent, this could be
possibly due to the closely related natures of Aurora A and B function, and
possibly due to direct overlap of some substrates.
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Table 2. Cancer Types Overexpressing Aurora B Kinase

Cancer Type

Reference

Colon cancer

(Katayama et al., 1999)

Thyroid cancer

(Sorrentino et al., 2005)

Oral cancer

(Qi et al., 2007)

NSCLC

(Smith et al., 2005)

Breast cancer

(Tchatchou et al., 2007)

Seminoma

(Chieffi et al., 2004)

Glioma

(Araki et al., 2004)

Hepatoma

(Lin et al.)

15

1.5 Tumor Suppressor p53- “Guardian of the Genome”
p53 is perhaps the most important gene in relation to cancer since it is
mutated or lost in 50% of all cancer types (Soussi and Wiman, 2007). p53 has
been described as the “Guardian of the Genome” (Lane, 1992) and is a key
transcription factor governing the integrity of the genome through multiple
pathways. p53 was first described as a protein that was bound to the large T
antigen of the SV40 virus (DeLeo et al., 1979; Kress et al., 1979; Lane and
Crawford, 1979; Linzer and Levine, 1979; Melero et al., 1979) and was first
thought to be an oncogene since it was found to be present in large amounts in
tumor cells. Later, p53 was found to be mutated in these cells and was actually a
tumor suppressor (Baker et al., 1989). Not only can mutated p53 contribute to
the formation of cancer, but this can also happen through the disruption of many
of the regulatory pathways that govern the activation of p53 (Oren, 2003).

The p53 protein is organized into four domains, the Transactivating
domain (TAD), the DNA binding domain, the Oligomerization domain and the
Basic domain (Figure 3). The Transactivating domain is broken up into three
parts: AD1, AD2 and the proline-rich region. AD1 and AD2 are on the Nterminal end and are where many of the myriad posttranslational modifications of
p53 occur as well as the binding of p53’s major negative regulator Mdm2 and the
two acetyltransferases, p300 and CBP (Espinosa and Emerson, 2001; Gu et al.,
1997; Stommel and Wahl, 2004). The proline rich region of the TAD contains
five copies of a PXXP motif, the function of which has not been well
characterized but which has been implicated in mediation of apoptosis and
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growth repression (Baptiste et al., 2002; Sakamuro et al., 1997; Walker and
Levine, 1996; Zhu et al., 1999). The DNA binding domain spans amino acids
102-292 and functions to bind to p53 response elements in DNA. Amino acids
323-356 make up the oligomerization domain, responsible for dimerization and
which also contains a nuclear export sequence (Nicholls et al., 2002). Last, the
Basic domain at the C-terminal end contains two nuclear localization sequences
(Shaulsky et al., 1990; Weinberg et al., 2004).

p53 is a member of the p53 gene family which includes the related genes
p63 and p73 (Kaghad et al., 1997; Yang et al., 2002). p63 and p73 both have
significant homology to p53 and can indeed function in the same way to activate
transcription of some of the same gene targets as p53. Knockdown mouse
models of each member of the p53 gene family produced distinct phenotypes,
indicating that while they can overlap in their target genes, they serve functionally
distinct purposes (Murray-Zmijewski et al., 2006). Just as p63 and p73 are
known to have many isoforms (p63=6, p73=35), p53 also has alternate splice
variants and more than one internal promoter which results in various isoforms.
Intron 9 and Intron 2 can be spliced alternate ways and intron 2 contains an
alternate promoter which leads to the expression of 9 isoforms of p53 (Bourdon
et al., 2005).

p53 is activated in response to many types of stress and mediates the
cellular responses of cell cycle arrest, apoptosis and senescence thereby
preventing a genomically unstable cell from proliferating. p53’s ability to mediate
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these responses is through its ability to bind DNA and regulate the transcription
of many target genes. p53 tetramerizes and binds p53 response elements
(p53REs) in DNA sequences (Bourdon et al., 1997; el-Deiry et al., 1992; Funk et
al., 1992). Major gene targets of p53 include: p21, GADD45, Bax, Puma, Noxa
14-3-3σ and Mdm2 (Vousden and Prives, 2009). p53 also has functions
independent of its transcriptional activity, one of which is its ability to translocate
to the mitochondria and promote apoptosis (Mihara et al., 2003).

Activation of p53 is mediated through several different types of cellular
stress including UV exposure (Maltzman and Czyzyk, 1984), DNA double strand
breaks due to ionizing radiation (Kastan et al., 1991) and replication stress
induced by oncogene expression (Bartkova et al., 2005; Gorgoulis et al., 2005).
In the latter example, oncogenes cause DNA replication errors inducing stalled
replication forks which trigger the DNA damage response in which kinases ATM
and Chk2 cause accumulation of p53. The N-teminus of p53 contains many
residues that are modified by acetylation, sumoylation, methylation, ubiquitination
and in the case of ATM and Chk2, phosphorylation (Harris and Levine, 2005).
These posttranslational modifications generally prevent the binding of p53 to
Mdm2 leading to p53 accumulation and activation (Lavin and Gueven, 2006). In
this way p53 forms a blockade against nascent tumor cells by mediating their
death through apoptosis and senescence.
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Figure
ure 3. Protein domains of the ttumor suppressor p53
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1.6 p53 Transcriptional Activity
p53 regulates its transcriptional activities by first sensing cellular stresses
from sensor proteins in various cellular processes. Several examples of this are
DNA dependent protein kinase (DNA-PK), which senses DNA strand breaks,
ATM, which senses ionizing radiation induced DNA damage, REDD-1, which
monitors ROS levels, AMPK, which detects nutrient deprivation and ATR, which
responds to UV induced DNA damage (Levine et al., 2006). Signaling from
these sensors triggers post-translational modification of p53, which results in
changes in p53 target gene expression. Generally, transcriptional activity is
regulated by direct binding of p53 to the promoter or first intron of the target
genes (Horvath et al., 2007; Wei et al., 2006), although gain of function and p53
transcriptional repression are also be investigated actively.

p53 effector genes fall into several distinct functional categories, cell cycle,
DNA repair, reactive oxygen species (ROS), apoptosis, miRNA, autophagy,
metabolism and autoregulation. These broad functional categories underscore
the number of genes p53 can affect. So far, there are 60 genes with validated
p53REs and no doubt many more to be discovered (Horvath et al., 2007). Global
mapping of the human genome for p53REs revealed 582 REs and identified 98
previously unknown effector genes (Wei et al., 2006).

p53’s function in DNA damage repair is one of the most studied and
important of its many capacities. Effector genes with p53REs have been found
to effect homologous recombination (HR), mismatch repair (MMR) and
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nucleotide excision repair (NER). For example, in nucleotide excision repair, p53
upregulates Xeroderma Pigmentosa group C (XPC) and DDB2 (Adimoolam and
Ford, 2002; Hwang et al., 1999; Tan and Chu, 2002; Tang et al., 2000). These
genes encode proteins that recognize DNA damage and induce NER.

In its caretaker of the genome role, p53 upregulates two genes that are
involved in ROS scavenging to prevent oxidative damage to proteins, DNA and
lipids. Glutathione Peroxidase 1 (GPX1) and Superoxide Dismutase 2 (SOD2)
both act as effectors in this case scavenging reactive oxygen species (Horvath et
al., 2007; Hussain et al., 2004; Tan et al., 1999).
Should DNA damage be too great to overcome, p53 can mediate
programmed cell death by upregulating genes like Bax, Puma and Noxa. Bax
codes for a proapoptotic Bcl-2 family gene that stimulates release of cytochrome
C from the mitochondria (Oltvai et al., 1993). Puma and Noxa are also p53
target genes as well as Bcl-2 family members and help to mediate cell death
through the Cytochrome C/APAF-1 pathway (Nakano and Vousden, 2001; Oda
et al., 2000). p53 increases Puma expression through two REs in its promoter
(Wang et al., 2007; Yu et al., 2003).

Another central function of p53 transcriptional control is arrest of the cell
cycle. This occurs mainly via regulation of cyclin dependent kinases or PCNA by
p21, resulting in G1/S arrest (Gibbs et al., 1997). p21 is a major target of p53
and contains six p53 REs in its promoter (Chen et al., 1995; Chin et al., 1997;
Hollander et al., 1993; Horvath et al., 2007; Wei et al., 2006). Similarly, G2/M
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arrest is controlled by p53 via GADD45 which has a p53 RE in its third intron
(Chen et al., 1995; Chin et al., 1997; Hollander et al., 1993). GADD45 exerts
control of the cell cycle by modulating the activity of Cyclin B1.

Autophagy has recently been described as an area of p53 transcriptional
control. p53 has been found to increase autophagy by controlling PTEN
expression which downregulates the mTOR pathway, a major negative
autophagic regulator (Feng et al., 2005). p53 has also recently been implicated
in metabolism and energy production as a regulator of Synthesis of Cytochrome
C Oxidase (SCO2) (Matoba et al., 2006).
A further regulation of metabolism by p53 is the discovery of TIGAR as a
p53 target. TIGAR lowers levels of fructose 2,6-bisphosphate, a substrate of 6phospho-1-kinase which is a promoter of glycolysis (Bensaad et al., 2006).

To maintain the balance of p53 in the cell, p53 also effects its own
regulation in an autoregulatory feedback loop with several E3 ubiquitin ligases.
Targets of p53 regulation that can facilitate p53 ubiquitination include Mdm2,
Pirh2 and Cop1(Millau et al., 2009).
1.7 Phosphorylation of p53
Phosphorylation of p53 is generally thought to increase accumulation of
p53 and increase p53 transcriptional activity, (Bode and Dong, 2004; Hupp and
Lane, 1994) and so far more than 20 phosphorylation sites have been found
(Table 3). Many of these events occur in the N-terminal TAD domain of p53,
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while some occur in the C-terminal Basic domain (Bode and Dong, 2004; Gatti et
al., 2000). There is some overlap in that some kinases share phosphorylation
sites and distinct kinases can phosphorylate more than one residue of p53. This
redundancy is not surprising considering the importance of p53 as a tumor
suppressor. The complicated picture of p53 phosphorylation can be explained by
the sheer number of genes p53 activates or represses. For many of these
genes, a simple on/off switch won’t do and this complex array of phosphorylation
sites may help to explain this. For example, a different and unique number of
phosphorylation events could be used to activate a certain subset of genes in
response to a certain cellular stress. Another model could be that a certain
combination of phosphorylations could recruit other p53 post translational
modifications to coordinate p53 binding to genes. A third way to think about it is
that all these phosphorylation sites could just be a failsafe mechanisim since loss
of regulatory control by p53 could be catastrophic (Meek and Anderson, 2009).
While most phosphorylation events that modify p53 result in activation of
p53 transcriptional activity, this is somewhat dependent on the domain being
modified. There is at least one kinase known to phosphorylate p53 in the DNA
binding domain thus interfering with p53’s ability to bind response elements.
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Table 3. p53 Phosphorylation Sites
Kinase

Site(s)

Domain

ABL1

Reference
(Agami et al., 1999; Gonfloni et al., 2009; Gong et
al., 1999; Yuan et al., 1999)

ATM

S15

TAD

(Huang et al., 2008)

CDK2

S315

NLS

(Gaiddon et al., 2003; Huang et al., 2008)

Chk1/2

S20

TAD

(Gonzalez et al., 2003)

Gsk3β

S315

NLS

(Patturajan et al., 2002)

HIPK2

S46

TAD

(Kim et al., 2002)

JNK1

S20,
T81

TAD

(Jones et al., 2007)

TAD,
Basic

(Koida et al., 2008; Mantovani et al., 2007;
Papoutsaki et al., 2005)

P38

S33,
S46,
S392

PLK1

(Koida et al., 2008)

Aurora A

S215,
S315

DBD,
NLS

(Katayama et al., 2004; Liu et al., 2004)

CK1

S6, S9,
T18

TAD

(Dumaz et al., 1999; Sakaguchi et al., 2000)
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1.8 Specific Aurora B Kinase Inhibitor AZD1152
Since the discovery of the Aurora kinases in the 1990s, they have been
considered excellent potential targets of cancer therapy due to both their central
role in mitosis and their overexpression in a variety of tumor types (Kitzen et al.).
Many Aurora kinase inhibitors have been developed in recent years, with a few
becoming candidates for clinical trials. One such inhibitor is the Aurora B
inhibitor, AZD1152. AZD1152 is a specific Aurora B kinase inhibitor developed
by Astra Zeneca (Mortlock et al., 2007). It is specific for Aurora B kinase at a
Ki=0.36 nM versus Aurora A kinase, Ki=1369 nM (Wilkinson et al., 2007).
AZD1152 is an acetanilide-substituted pyrazole-aminoquinazoline prodrug that is
converted quickly to the active drug AZD-1152 hydroxy-QPA (AZD1152-HQPA)
in human plasma (Mortlock et al., 2007; Wilkinson et al., 2007)(Figure 4).
Consistent with inhibition of Aurora B, AZD1152 causes improper cytokinesis,
polyploidy, cell cycle arrest, apoptosis, chromosome mis-segregation and
chromosome misalignment.

AZD1152 has been evaluated in several preclinical studies in the last few
years and has been shown effective in a variety of tumor types including
colorectal, hepatocellular carcinoma, lung, multiple myeloma and several
hematologic malignancies. Human colorectal SW620 cells showed dose
dependent inhibition of p-HH3 at serine 10 when treated with AZD1152.
Impressively, in SW620 nude mouse xenografts, one dose of AZD1152 at 150
mg/kg/day reduced mean tumor volume by 80% (Wilkinson et al., 2007).
AZD1152 was also shown effective in lung and hematologic cancers. Doses of
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10-150 mg/kg/day were able to reduce tumor growth in A549, HL-60 and Calu-6
xenografts (Cheung et al., 2009). Consistently, AZD1152 was shown effective in
inhibiting the cell growth of AML, ALL, biphenotypic leukemia, acute eosinophilic
leukemia, blast stage CML (Yang et al., 2007) and multiple myeloma (Evans et
al., 2008) cell lines. Further, radiosensitivity was shown to be increased with
AZD1152 treatment in Hct116 cell xenografts (Tao et al., 2008). AZD1152 is
currently being investigated in patients with advanced solid malignancies and is
in use in a phase I clinical trial for relapsed AML (Boss et al.).
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Phosphatase

Figure 4. Specific Aurora B kinase inhibitor AZD1152 (2-(3-((7-(3-(ethyl(2hydroxyethyl)amino)propoxy)quinazolin
hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3fluorophenyl)acetamide) prodrug is converted to the active metabolized form
AZD1152-HQPA.
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1.9 Aurora Kinases and p53
Since p53 is not known to have a function in mitosis, and the Aurora
kinases are generally thought to have mitotic-specific functions, there have been
few studies that have evaluated the interaction or potential phosphorylation of
p53 by Auroras. However, Aurora A kinase has been linked to p53
phosphorylation by at least two separate studies. The first, in 2003, described
the phosphorylation of p53 by Aurora A at serine 315 which resulted in
decreased p53 level and transcriptional activity due to subsequent p53
destabilization and degradation mediated by Mdm2 (Katayama et al., 2004). In
contrast, a previous study found that this phosphorylation site increased p53
activity and was linked to DNA damage induced by UV radiation. The authors
also described the phosphorylation being inhibited by the cdk inhibitor
Roscovitine (Blaydes et al., 2001). A subsequent study of Aurora A
phosphorylation of p53 found an additional site at serine 215 and indicated that
this site, and not serine 315, was important for p53 stability and transcriptional
activity (Liu et al., 2004). Consistent with the findings that p53 is phosphorylated
by Aurora A, it was found that p53 also localizes to the centrosome in an ATM
dependent manner (Tritarelli et al., 2004).

Although several studies have linked Aurora A to phosphorylation of p53,
the picture remains cloudy due to conflicting reports of which sites are important
and whether they activate or suppress p53 function. Additionally, to date no
study has found p53 phosphorylation by either Aurora B or Aurora C.
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1.10 Rationale and Hypothesis
It is known that Auroras A and B are both overexpressed in breast cancer
(Fu et al., 2007; Keen and Taylor, 2004) and several studies have evaluated the
importance of the Auroras in breast cancer. Consistently, Aurora A
overexpression was shown to induce breast tumor formation in mouse epithelium
(Wang et al., 2006). Further, it was found that polymorphisms in the Aurora A
gene were closely tied to increased risk of breast cancer (Cox et al., 2006;
Fletcher et al., 2006) and that this increased risk was more dangerous in women
with prolonged exposure to estrogen (Dai et al., 2004). Two small studies found
Aurora A overexpression in 94% of invasive ductal carcinoma (Tanaka et al.,
1999) and 64% of breast cancer cases by mRNA analysis (Miyoshi et al., 2001).

Less data is available for Aurora B’s importance in breast cancer although
Aurora B was shown to be induced by estrogens resulting in cellular proliferation
in preclinical models (Ruiz-Cortes et al., 2005) and a specific polymorphism of
the Aurora B gene (885A>G) has been shown to increase the risk for breast
cancer in these individuals (Tchatchou et al., 2007). Given the known
overexpression of Aurora kinases in breast cancer and that Aurora A kinase
phosphorylates p53 resulting in decreased p53 activity, it stands to reason that
inhibition of Aurora B with a specific kinase inhibitor could produce antitumorigenic effects in breast cancer by inhibiting possible phosphorylation of p53
by Aurora B.
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Hypothesis: Inhibition of Aurora B kinase reduces tumorigenesis in breast
cancer by increasing p53 protein level and transcriptional activity.
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Chapter 2. Materials and Methods
2.1 Tissue Culture
HER18 cells, which are Her2 stable transfectants of MCF7 breast cancer
cells, are described previously (Laronga et al., 2000). They were cultured in
DME/F12 (Sigma, St. Louis, MO) supplemented with either 5% or 10% fetal
bovine serum (Gemini, West Sacramento, CA). MDA-MB-468, MDA-MB-435,
MDA-MB-361, BT-474 and MDA-MB-468 were obtained from the ATCC
(Manassas, VA, USA). MDA-MB-231, MDA-MB-435 and MDA-MB-468 cells
were maintained in Leibovitz’s L15 media (Cellgro, Manassas, VA) with 10% fetal
bovine serum. BT-474, MDA-MB-361, 293T, H1299, MCF7 and Hela cells were
also obtained from the ATCC and were maintained in DME/F12 media (In house
supplier) supplemented with 5% or 10% (v/v) fetal bovine serum. U2OS (ATCC),
Hct116 p53 +/+ and Hct116 p53 -/- (a kind gift from Dr. Bert Vogelstein) (Bunz et
al., 1998) were cultured in McCoy’s 5A media (Hyclone), supplemented with 5%
or 10% fetal bovine serum. All cells were incubated with 5% CO2 and maintained
in a humidified 37 oC incubator with 2 mM L-glutamine (Cellgro, Manassas, VA)
and 1% antibiotic-antimycotic solution (Invitrogen, Grand Island, NY).

2.2 Drugs, Reagents, Antibodies
AZD1152 (prodrug) and AZD1152-HQPA (metabolized form) were a kind
gift from Dr. Kirsten Mundt (Astra Zeneca, Macclesfield, Cheshire, UK).
AZD1152-HQPA (metabolite) was prepared in 100% DMSO at 10 mM
concentration, and used as indicated. AZD1152 (prodrug) was prepared in 0.3 M
Tris (pH 9.0) (Fisher, Pittsburgh, PA) and 0.2% DMSO (Fisher). AZD1152
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solution was made fresh at a maximum of 20 mg/ml for each cycle of injections
into nude mice. De novo protein synthesis inhibitor, cycloheximide and
proteasome inhibitor MG132 were obtained from Sigma (St. Louis, MO) and used
at 100 µg/ml and 5 µg/ml respectively. MG341 (Velcade, Bortezomib) was
purchased from Millenium Laboratories (San Diego, CA) and used at 70 ng/ml
overnight. Cisplatin was purchased from Bedford Laboratories (Bedford, OH)
and used as indicated.
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Table 4.

Antibody List

Antigen

Method

Source

Manufacturer

Cat/Clone

14-3-3σ

IB

Mouse

RDI

1433S01

Actin

IB

Rabbit

Sigma

A2066

Annexin V-FITC

FACS

Mouse

BD Biosciences

556419

Aurora B

WB, IF

Rabbit

Abcam

Ab2254

Bad

IB

Mouse

BD Biosciences

B36420

BD Transduction
Bax

IB

Mouse

labs

B73520

Caspase 3

IHC

Rabbit

Cell Signaling

9661

Cyclin A

IB

Rabbit

Santa Cruz

SC751

Cyclin B1

IB

Mouse

Santa Cruz

SC245

Cyclin D

IB

Mouse

Neomarkers

MS-2110

Cyclin E

IB

Mouse

Santa Cruz

SC-247

Flag

IB, IP

Mouse

Sigma

A804-200

GFP

IB, IP

Mouse

Santa Cruz

SC-9996

HA

IB,IP

Mouse

Roche

12CA5

His

IB

Rabbit

Santa Cruz

SC-803

HH3 (p-S10)

IB

Rabbit

Upstate

05-817
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Ki-67

IHC

Rabbit

Abcam

Ab66155

Mdm2

IB

Rabbit

Santa Cruz

S3813

IP, IF

Mouse

Sigma

I5381

IB

Goat

Pierce

32430

IF

Goat

Molecular Probes

A11029

568)

IF

Goat

Molecular Probes

A11031

P53

IHC,WB,IP

Rabbit

Santa Cruz

SC-6243

P53

IF

Mouse

BD Biosciences

610183

P53 (p-S315)

IB

Rabbit

Cell Signaling

2528S

PARP

IB

Mouse

BD Biosciences

516639GR

P21

IB

Mouse

Transduction Labs

610233

PUMA

IB

Rabbit

Santa Cruz

SC-28226

IF

Goat

Molecular Probes

A1103

IF

Goat

Molecular Probes

A11011

Mouse IgG nonimmune
Mouse IgG (HRP
conj.)
Mouse IgG (Alexa
488)
Mouse IgG (Alexa

Rabbit IgG (Alexa
488)
Rabbit IgG (Alexa
568)
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Rabbit IgG nonimmune

IP, IF

Rabbit

Sigma

R5756

conj.)

IB

Goat

Pierce

32460

Survivin

IF

Rabbit

Cell Signaling

2808

Tubulin

IB

Mouse

Sigma

T5168

Rabbit IgG (HRP
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2.3 Proliferation and IC50 Determination
To determine amount of proliferation and IC50, an MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) assay was
utilized. Indicated cells were seeded at 5-20% confluence and allowed to attach
for 24 hours. AZD1152-HQPA was applied following serial dilutions in
appropriate complete media to the indicated concentrations. 96 well Plates were
incubated for between 2 and 5 days. After incubation, 20 µl MTT was applied to
each well and then incubated for 1 to 5 hours. After incubation, media was
replaced with 200 µl 100% DMSO (Fisher). Plates were mixed on a rotary mixer
at room temperature and 50 rpm then read using an MRX revolution plate
spectrophotometer (Dynex, Technologies, Chantilly, VA) at 570 nm. Averages
were plotted from 4 replicates and 50% inhibitory concentration (IC50) was
determined based on sigmoidal curve fitting (Sigma plot, Systat Inc.). The MTT
method was validated using live counts of Her18 cells plated in a similar fashion
in 3.5 cm2 tissue culture plates. Cells received a similar treatment with AZD1152HQPA and were counted using a Z1 Coulter particle counter (Beckman Coulter,
Fullerton, CA). Average numbers of cells from triplicate plates were plotted
against the concentration of AZD1152-HQPA.
2.4 Colony Forming Assays
2.4.1 Adherent Culture.
Adherent colony (foci) forming assays were performed in triplicate by
plating indicated cell lines in 6 cm2 tissue culture dishes. Cells were plated at
approximately 5000 cells/plate in complete DME/F12 medium with either 40 nM
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AZD1152-HQPA or vehicle (DMSO, Fisher). Plates were maintained in a 37 °C
incubator for 12 days with 5% CO2. Colonies (foci) were counted in three
representative one cm2 areas per plate and the number colonies per cm2
recorded. Differences between the AZD1152-HQPA-treated cells and vehicle
treated cells were compared using a Student’s t-test.
2.4.2 Suspension Culture
Soft agar colony forming assays were performed in triplicate plates with a
base agar of 1X DME/F12 complete medium with 0.5% low melt agar (Fisher)
and either DMSO for the control or 80 nM AZD1152-HQPA. Base agar was
added to 6 cm2 Petri dishes and allowed to set. 5000 cells/plate added to 0.35%
top agar with control medium or 80 nM AZD1152-HQPA was poured over the
bottom agar. The plates were incubated at 37 °C with 5% CO2 for 26 days.
Colonies >100 cells were counted using a dissecting microscope, and results
were analyzed using the Student’s t-test.
2.5 Immunofluorescence
Indicated cell lines were grown in either chamber slides, tissue culture
dishes or on cover glasses to 50-75% confluence. Cells were treated with
vehicle, 20 nM AZD1152-HQPA or received no treatment for 48 hours. Cells
were rinsed 2x with cold PBS (in house) and then fixed with 3%
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) solution for 15
minutes at room temperature. Cells were then rinsed 3x with cold PBS, 10
minutes each followed by permeabilization with 0.2% Triton X-100 (Sigma).
Plates were blocked in either 5% BSA (Sigma) or 5% normal goat serum (a kind
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gift from Dr. Elsa Flores) and diluted in PBS for one hour. Fixed and blocked
cells were then stained with antibodies (See Table 4), primaries were diluted
appropriately in PBS an applied for a period of one hour to overnight. Cells were
stained with either DAPI and mounted on microscope slides using Fluoromount
G (Southern Biotech, Birmingham, AL) or they were mounted in Prolong Gold
(Invitrogen) which contained DAPI. Immunostained cells were visualized with an
Olympus IX81 confocal microscope, an Olympus IX70 fluorescent microscope, a
PerkinElmer Ultraview ERS spinning disk confocal microscope or a Nikon Ti with
a Photometric CoolSnap HQ2 camera driven by Nikon Elements software.
Deconvolved images were processed using AutoQuant X2 software from Media
Cybernetics software.
2.6 Immunoblotting and Immunoprecipitation
Cells for Western blot or immunoprecipitation were scraped from tissue
culture dishes after two rinses with cold PBS. Cells were then centrifuged at low
speed for 10 minutes and supernatants discarded. Pellets were then either
frozen at -80 °C for further processing later or they were lysed with 100-300 µl 1x
lysis buffer (0.5 L batch: 7.5g 1 M tris [Fisher], 15 ml 5M NaCl [Fisher], 0.5 ml
NP-40 [USB Corp.], 0.5 ml Triton X-100 [Sigma] and 1 ml 0.5M EDTA [Fisher])
for 20 minutes at 4°C. Lysis buffer also contained a cocktail of
protease/phosphatase inhibitors: 5 mM NaV, 1 mM NaF, 1 µM DTT, 0.1 mg/ml
Pepstatin A, 1 mM PMSF and 1000x Complete Cocktail Protease Inhibitor
(Roche). Lysates were centrifuged at high speed for 10 minutes and cell debris
discarded. Protein concentration was measured using the Bradford method with
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protein assay reagent (Biorad) and read on Powerwave XS (Biotek)
spectrophotometer at 595 nm. Protein samples were standardized and mixed
with 5x loading dye (100 ml batch: 3.78 g Tris base, 5 g SDS, 25 g sucrose
[Sigma] and 0.04 g bromophenyl blue [Sigma], pH adjusted to 6.8) and boiled 5
minutes prior to SDS-gel analysis. SDS-PAGE was performed according to
standard procedures. All gels were 10% except: Mdm2 8%, p-HH3 15%, Bax
15%, oligomerization of p53 6% and p21 15%. Transfer of proteins was
performed using 1x transfer buffer (1 L batch: 30.3 g tris base, 144 g glycine
[Fisher] and 10 g SDS, pH adjusted to 8.3) to PVDF membrane (Millipore). For
immunoprecipitations, cell lysates were prepared and standardized as before and
1 mg protein immunoprecipitated with appropriately diluted antibody in lysis
buffer overnight. Antibody was then pulled down with 50 µl of either Protein A or
G beads (Santa Cruz) for 1 hour. Beads were then centrifuged at low speed for
10 minutes and supernatant discarded. Beads were rinsed 3x in lysis buffer with
inhibitors and dried with a 27 gauge needle. Dried beads were mixed with 2x
loading dye (5x loading dye diluted 1:2.5) and boiled 5 minutes. Lysates were
loaded into gels and SDS-PAGE performed as before.
2.7 Fluorescence Sorting
2.7.1 Cell Cycle Analysis
Cells to be analyzed were plated in 6 well tissue culture dishes and grown
to log phase. Appropriate treatments by either transfection of plasmids or
treatment with AZD1152-HQPA were performed and allowed to proceed for 2448 hours. Monolayers were rinsed twice with PBS and cells scraped into
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microcentrifuge tubes. Cells were centrifuged at low speed and rinsed once with
PBS. Pellets were resuspended in 0.5 ml hypotonic PI solution (50 ml batch:
0.85 mg/ml sodium citrate (Sigma) 0.1 mg/ml RNase A (Qiagen, Valencia, CA),
0.1% Triton X-100, 20 mg/ml PI (Roche) and incubated in the dark for 30
minutes. Cell cycle/PI analysis was performed using a FACScalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
2.7.2 Measurement of Apoptotic Cells
Cells to be analyzed for apoptosis were plated in 10 cm2 or 6 well tissue
culture dishes and allowed to attach for 24 hours. Treatments with AZD1152HQPA or transfection were allowed to proceed 24-48 hours prior to harvest. At
harvest, cells were washed with PBS and collected by scraping. Cells were
centrifuged at low speed and washed twice with PBS and resuspended in 0.5 ml
binding buffer (Axxora, San Diego, CA) containing 5 µl Annexin V-FITC (BD, San
Jose, CA) for 15 minutes at room temperature. Cells were washed once more in
PBS, and PI solution with RNAseA (500 mg/ml, Roche) was applied.
2.8 Cell Cycle Synchronization
2.8.1 Double-Thymidine Block
Hct116, Hela or 293T cells were plated in appropriate complete media and
grown to 25-30% confluence. 2 mM thymidine (Sigma) was added to the media
for 18 hours followed by release by washing 2x with warm PBS and fresh
complete media refeed. Cells were allowed to grow 9 hours without block. After
9 hours, cells were again treated with 2 mM thymidine for 17 hours (second
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block). After second block, cells were released as before. At this point
approximately 90% of cells are synchronized to S phase.

2.8.2 Thymidine-Nocodazole block
Hct116, Hela or 293T cells were synchronized by plating to 40%
confluence in normal complete media. 2mM thymidine was added for 24 hours
followed by release by washing 2x with warm PBS and refeed with fresh
complete media. Cells were released for 3 hours and 100 ng/ml nocodazole
(Sigma) was added to the media for 12 hours. Cells were then released again
using 2x PBS wash and refed with fresh complete media. At this point,
approximately 75% of cells were synchronized to pro-meta phase.

2.9 Dual Luciferase Reporter Assays
Analysis of p53 transcriptional activity was performed by transfecting log
phase cells planted in 12 well tissue culture dishes with either a p53 luciferase
reporter plasmid containing the 3 copies of the p53 binding sites from the 14-33σ or Mdm2 promoters. Cells were also transfected with the Renilla luciferase
reporter plasmid. Following transfection, cells were treated with either AZD1152HQPA or vehicle and incubated for 24 hours. At harvest, cells were collected
using 1x passive lysis buffer (Promega) and analyzed according to the
manufacturer’s protocol with the Dual Luciferase Reporter Assay kit (Promega).
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2.10 Nude Mouse Xenograft Assays
2.10.1 Orthotopic Xenograft Model
Female athymic (6-8 weeks of age) nude mice (Experimental Radiation
Oncology, MD Anderson Cancer Center) were maintained in AAALAC approved
facilities with food and water ad libitum on a 12-hour light/dark cycle. Mice were
housed and treated under an approved protocol in compliance with all animal
care and use guidelines (AALAS) of our institution. Twenty four nude mice were
injected in the mammary fat pad with 8.5 x106 Her18 human breast cancer cells
(McKenzie et al., 2004; Warburton et al., 2004). Weekly subcutaneous estradiol
cypionate (Pfizer, NY, NY) injections were administered at 3 mg/kg/week
beginning 2 weeks before injections of Her18 cells (Jerome et al., 2006; Wang et
al., 2004). Following tumor cell injection, mice were randomly divided into 3
groups. AZD1152 prodrug treatment began when tumors were greater than 50
mm3. Mice in the control group received IP injections of vehicle (0.3 M Tris pH
9.0), mice in the low dose group received 62.5 mg/kg/day of AZD1152 and high
dose mice received 125 mg/kg/day AZD1152. Drug or vehicle was administered
on day 1 and 2 of a 7-day repeating cycle which lasted for 3 cycles. Tumor
volume estimates were performed by measuring the tumors every 2 to 3 days
with calipers and applying the formula: Length x Width2 /2 (Osborne et al.,
1985). After 24 days, mice were sacrificed and tumors excised. Some tumor
samples were snap-frozen for protein extraction followed by Western blotting and
others fixed in formalin and paraffin embedded for immunochemistry analysis.
The ABC kit (Vector Labs) was used for IHC staining. Photomicrographs of IHC
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sections were taken at 200x magnification using an Olympus IX70 microscope.
Images were recorded and processed with Olympus DP controller imaging
software (version. 3.2.1.276).
2.10.2 Metastatic Xenograft Model
Nude mice (6-8 weeks of age) were injected with 2 x106 MDA-MB-231
cells by tail vein. Prior to injection, cells were suspended in 200 µl complete
media. Mice were then randomly separated into 2 groups (control and 125
mg/kg/day AZD1152 prodrug). Injections were performed on day 1 and 2 of a
weekly cycle for 4 cycles beginning two days post tumor cell injection. Vehicle
(0.3 M Tris pH 9.0) injections were given to control mice. 10 weeks after tumor
cell injection, mice were sacrificed and the lungs excised followed by weighing
and examination for tumor nodules. Lungs were fixed in formalin and analyzed
by IHC staining as before.
2.11 Construction of Mutants
Aurora B and p53 mutants were constructed using a site directed
mutagenesis technique. Forward and reverse primers (complementary) that
were approximately 30 bases long were used in a PCR reaction with PFU Turbo
polymerase (Stratagene) to amplify plasmids in their entirety. The primers were
designed to change one or two bases to effect the change in the amino acid
sequence. See Table 5 for plasmid list and primers used in this process. After
amplification, plasmids were treated with restriction enzyme DpnI (New England
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Biolabs) to digest any remaining template. Plasmids were then transformed into
DH5α E. coli (in house) and selected with appropriate antibiotics.
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Table 5.

Plasmid List
Plasmid

Source or Primer Sequence

Flag-Aurora B

Subrata Sen

GFP-Aurora B

Subrata Sen

GFP-p53

Jeffrey Wahl (Stommel et al., 1999)

His-p53

Zeev Ronai

P53 (no tag)

Mong-Hong Lee

HA-Ubiquitin

Edward Yeh

GST-p53

Jiandong Chen

GST-p53 (1-160)

Jiandong Chen

GST-p53 (160-393)

Jiandong Chen

GST-p53 (320-393)

Jiandong Chen

Venus C-term

Gordon Mills (Ding et al., 2006)

Venus N-term

Gordon Mills (Ding et al., 2006)

Venus C-term-AurB

For 5’ –GTAATAGGCGCGCCATGGCCCAGAAGGAGAA– 3’
Rev 5’ –CATTAAGAATTCTCAGGCGACAGATTGAA– 3’

Venus N-term-p53

For 5’ –GATATTGGCGCGCCATGGAGGAGCCGCAGTC– 3’
Rev 5’ –CTATAAGAATTCTCAGTCTGAAGTCAGGCC– 3’

Flag-Aurora B K106R

For 5’ – TCATCGTGGCGCTCAGGGTCCTCTTCAAGT – 3’
Rev 5’ – ACTTCAAGAGGACCCTGAGCGCCACGATGA – 3’

GST-p53 S183A
GFP-p53 S183A

For 5’ –CCATGAGCGCTGCGCAGATAGCGATGGTCT– 3’
Rev 5’ –AGACCATCGCTATCTGCGCAGCGCTCATGG– 3’
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GST-p53 T211A
GFP-p53 T211A

For 5’ –CACACTATGTCGAAAAGCGTTTCTGTCATC– 3’
Rev 5’ –GATGACAGAAACGCTTTTCGACATAGTGTG– 3’

GST-p53 S215A
GFP-p53 S215A

For 5’ –TTCGACATGCTGTGGTGGTGCCCTATGAGC– 3’
Rev 5’ –GCTCATAGGGCACCACCACAGCATGTCGAA– 3’

GST-p53 S269A
GFP-p53 S269A

For 5’ –ACTGGGACGGAACGCCTTTGAGGTGCATGT– 3’
Rev 5’ –ACATGCACCTCAAAGGCGTTCCGTCCCAGT– 3’

GST-p53 T284A
GFP-p53 T284A

For 5’ –AGAGACCGGCGCGCAGAGGAAGAGAATCTC– 3’
Rev 5’ –GAGATTCTCTTCCTGTGCGCGCCGGTCTCT– 3’

Renilla-luciferase

Zeev Ronai

P53-luc. (14-3-3σ)

Bert Vogelstein

P53-luc. (Mdm2)

Gigi Lozano

GFP-p53 S183A, S215A

See primers above

GFP-p53 S183A, T211A, S215A

See primers above

shRNA AurB 468

Sigma Mission shRNA (NM_004217.x-468

shRNA AurB 1185

Sigma Mission shRNA (NM_004217.x-1185)

pCMV5

David Russell (Andersson et al., 1989)

His-Ubiquitin

Hui-Kuan Lin
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2.12 In Vitro Kinase/Binding Assays
IP purified Aurora B (immunoprecipitation described previously) or
recombinant Aurora B (Cell Signaling) were incubated in 1x kinase buffer (80 mM
MOPS [Sigma], 7.5 mM MgCl [Fisher], pH 7.0) with GST-purified p53 substrates,
cold ATP and γ32 ATP (Perkin Elmer) at 30 °C for 15 minutes. Kinase reactions
were mixed with 5x loading dye and analyzed by SDS-PAGE as described
before. SDS-PAGE gels were dried and imaged using a phosphoimager
cassette (Molecular Dynamics) and a Typhoon Trio variable mode imager.
Images were processed using Image Quant 5.1. p53 substrates were produced
by growing BL-21 E. Coli (in house) containing the GST-p53 plasmid of interest
in 250 ml LB for 1 hour followed by induction of expression with 1mM IPTG
(Fisher). Cells were grown for 4 hours and harvested by centrifugation. Cells
were lysed with NETN buffer (20 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM
EDTA, 1% (v/v) Nonidet P‐40) plus inhibitor cocktail (see Section 2.6) and
sonicated 5 minutes. Cell debris was removed by high speed centrifugation and
200 µl GST beads (GE Healthcare) added. Lysates were incubated with beads
overnight at 4 °C. The following day, beads were spun low speed and washed 3
times in NETN plus inhibitors followed by one wash in 1x kinase buffer. p53
substrates for in vitro binding assays were prepared as for kinase assays.
Substrates were incubated with IP purified Flag-Aurora B overnight in 1 ml lysis
buffer. GST- tagged substrates were pulled down using GST beads and
immunoprecipitates analysed by SDS-PAGE followed by Western blotting with
anti-flag antibody.
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2.13 Ubiquitination Assays
Ubiquitination assays were performed as described in section 2.6 with the
exceptions that MG132 was added to transfected cells 6 hours prior to harvest
and upon lysis 0.1 µM NEM (N-ethylmaleimide) (Sigma) was added to lysis buffer
as well as inhibitors described previously. Standard procedures for Western
blotting were then applied.
2.14 Quantitative Real Time PCR
Total RNA was extracted from 293T, Her18 or Hct116 p53 -/- cells by
TRIzol (Invitrogen) according to the manufacturer’s instructions. Reverse
transcription was performed according to the manufacturer’s instructions using
the iScript cDNA synthesis kit (Biorad). 1 µl per reaction of cDNA product was
employed in quantitative real-time PCR according to the manufacturer’s
instructions with the iQ SYBR Green Supermix (Biorad) and iCycler (BioRad)
thermocycler. The following cycle was used: 95 °C for 10 minutes (1 cycle), 95
°C 15 s, 60 °C 1 min, 95 °C 15 s (40 cycles) and 95 °C 15 s, 60 °C 1min (1
cycle). Nucleotide sequences of forward and reverse primers are listed in Table
6.
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Table 6.

qRT-PCR Primers

p53 For.
p53 Rev.

5’ - CCGCAGTCAGATCCTAGCG - 3’
5’ - AATCATCCATTGCTTGGGACG - 3’

Mdm2 For.
Mdm2 Rev.

5’ - CCTTCGTGAGAATTGGCTTC - 3’
5’ - CAACACATGACTCTCTGGAATCA - 3’

p21 For.
p21 Rev.

5’ – CCTGTCACTGTCTTGTACCCT - 3’
5’ – GCGTTTGGAGTGGTAGAAATCT - 3’

Bax For.
Bax Rev.

5’ - CCCCGAGAGGTCTTTTTCCG - 3’
5’ - GGCGTCCCAAAGTAGGAGA - 3’

14-3-3σ For.
14-3-3σ Rev.

5’ – CTCTCCTGCGAAGAGCGAAAC - 3’
5’ – CCTCGTTGCTTTTCTGCTCAA - 3’

PUMA For.
PUMA Rev.

5’ - GACCTCAACGCACAGTACGAG - 3’
5’ - AGGAGTCCCATGATGAGATTGT - 3’

GAPDH For.
GAPDH Rev.

5’ – AGAAGGCTGGGGCTCATTTG - 3’
5’ - AGGGGCCATCCACAGTCTTC- 3’
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2.15 Venus Fusion Interaction Assays
Venus plasmids were a kind gift from Gordon Mills and were modified to
contain Aurora B and p53 by subcloning. Primers for Aurora B and p53 were
designed to contain AscI and EcoRV restriction sites. See Table 5. Cells were
transfected by the liposome method with Venus plasmids containing Aurora B,
p53 or empty Venus plasmids as appropriate controls. After 24 hours, cells were
imaged as described in Section 2.5.
2.16 Statistical Analyses
Statistical analyses including student’s t test, one way ANOVA, Tukey,
Rank sum and analysis of mixed linear models were performed using SigmaPlot
version 11 (Systat Software).
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Chapter 3. Results
3.1 Inhibition of Aurora B kinase causes antineoplastic effects in breast
cancer.

3.1.1 AZD1152 inhibits breast cancer growth regardless of Her2
status.
To evaluate the effect of specific Aurora kinase inhibitor, AZD1152, in
breast cancer, six breast cancer cell lines were treated for between 2 and 5 days.
Half of the cell lines tested, MDA-MB-435, MDA-MB-468 and MDA-MB-231 were
all normal for Her2 expression, an important marker in breast cancer and
indicator of potential treatment. Normal expression of Her2 is considered to be
negative since they do not overexpress Her2, as do other breast cancers at high
levels. Figure 5 shows that these cell lines are all sensitive to AZD1152-HQPA
(prodrug, see Figure 4) activity with IC50s of 125 nM, 14 nM and 105 nM
respectively. IC50 is the dose of the drug that inhibited 50% of cell growth and
was determined by sigmoidal curve fitting of the optical density reading at 570
nm after treatment with MTT. Next, I evaluated the use of AZD1152-HQPA in
breast cancer cell lines that overexpressed Her2. Figure 6 shows that three cell
lines, BT474, MDA-MB-361 and Her18 (parent line MCF7, described here
(Laronga et al., 2000), which all overexpress Her2 also had sensitivity to
inhibition of Aurora B kinase. IC50s were comparable to those from non Her2
expressing lines at 8 nM, 70 nM and 20 nM respectively. Further, to validate the
MTT assay as an effective method for investigating the proliferation of breast
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cancer cell lines, the inhibition curve of AZD1152-HQPA in Her18 cells was
repeated and cell numbers were measured directly by cell count. Figure 7 shows
that the live cell count IC50 agrees with that of the MTT assay for Her18 cells. All
cell lines tested displayed typical sigmoidal dose response curves for treatment
with AZD1152-HQPA. The IC50s observed are typical of those found for
leukemia and other human cancer cells (Wilkinson et al., 2007; Yang et al.,
2007). These results indicate that AZD1152-HQPA effectively inhibited growth of
human breast cancer cell lines regardless of Her2 status. See APPENDIX A for
AZD1152-HQPA dose response curves for other cell types and APPENDIX D for
analysis of synergy between AZD1152 and etoposide.
3.1.2 AZD1152-HQPA induces mitotic defects, G2/M arrest and
polyploidy in breast cancer cells.

Since Aurora B is an important regulator of mitosis, the effects of
AZD1152-HQPA on separation of chromosomes in mitotic Her18 cells was
investigated. Cells were treated with 20 nM AZD1152-HQPA for 48 hours
followed by staining with DAPI and imaging with a confocal microscope. While
normal cells displayed normal morphology, interphase cells treated with
AZD1152-HQPA were bi-nucleate, an indicator of mitotic slippage (Figure 8, top
panel, arrow). Also with AZD1152-HQPA treatment, micronuclei, indicators of
mis-segregated chromosomes, were observed. During mitosis, prophase
appeared normal but metaphase and anaphase showed considerable numbers
of mitotic defects including misaligned chromosomes, anaphase bridges and mis-
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segregation. Quantification of mitotic defects was performed and it was found
that 60% of cells treated with AZD1152-HQPA had defects versus 1-2% for
control (Figure 8, bottom panel). These results show that AZD1152-HQPA
effectively causes mitotic catastrophe in Her18 breast cancer cells and that these
observations are consistent with loss of Aurora B activity.

To further analyze mitotic outcome after treatment with AZD1152-HQPA,
Her18 cells were treated for up to 48 hours and stained with propidium iodide
followed by analysis by FACS for DNA content. The results indicate that the
number of 4N cells increased with drug treatment in a time exposure to the drug
(Figure 9A). Consistently, the number of 2N cells decreased and at the 48 hour
time point, 8N (polyploidy) cells were observed. This in consistent with mitotic
slippage caused by a defective spindle assembly checkpoint and is also
consistent with loss of Aurora B. Percentage of 2N, 4N and 8N cells from 9A
were quantified and are displayed in Figure 9B. It can be seen that as 4N cell
percentage increases, there is a decrease in the percentage of 2N cells. Figure
9C shows the fold increase of polyploid 8N cells from 9A. At 48 hours, polyploid
cells had increased to 9.7% from 1.35% at 24 hours, a 13 fold increase. These
results, together with the mitotic defect data from Figure 8, indicate that cells
become polyploid as mitotic catastrophe occurs with treatment of AZD1152HQPA. See APPENDIX B for analysis of polyploidy induced by AZD1152-HQPA
in the Her18 parent cell line, MCF7.
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Figure 5
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Figure 5. AZD1152-HQPA inhibits breast cancer cell growth in Her2
negative cell lines. Three breast cancer cell lines, MDA-MB-435, MDA-MB-468
and MDA-MB-231 that are all normal for Her2 (considered Her2 negative or not
overexpressing) were treated with indicated doses of AZD1152-HQPA for
between 2 and 5 days. After drug treatment, cells were treated with MTT and
log(dose)-response curves plotted. Data points are means of at least four
replicates. IC50 was determined by sigmoidal curve fitting. Error bars represent
95% confidence intervals.

55

Figure 6
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Figure 6. AZD1152-HQPA inhibits breast cancer cell growth in Her2
overexpressing cell lines. Three breast cancer cell lines, BT474, MDA-MB-361
and Her18 that all overexpress Her2 (Her18 is Her2 overexpression by lentivirus
infection- parent MCF7) were treated with indicated doses of AZD1152-HQPA for
between 2 and 5 days. After drug treatment, cells were treated with MTT and
log(dose)-response curves plotted. Data points are means of at least four
replicates. IC50 was determined by sigmoidal curve fitting. Error bars represent
95% confidence intervals.
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Figure 7. AZD1152-HQPA
HQPA inhibits breast cancer cell growth in Her18
Her as
measure by live cell count
count. Her18 cells were plated in 6-well
well tissue culture
dishes and incubated with AZD1152
AZD1152-HQPA
HQPA for 48 hours. Live cell counts were
performed and plotted against dose of drug. Data points represent mean of
three replicates. IC50 was determined by sigmoidal cur
curve
ve fitting. Error bars
represent 95% confidence intervals.
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Figure 8
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Figure 8. AZD1152-HQPA induces mitotic defects in Her18 breast cancer
cells. Top panel. Her18 cells were treated for 48 hours with AZD1152-HQPA or
control medium followed by DAPI staining. Fluorescence images of interphase
cells show bi-nucleation (arrow) and micronuclei (arrow heads). Misaligned
chromosomes are indicated by arrows in metaphase. Anaphase cells show
anaphase bridges (arrow head) and mis-segregated chromosomes (arrow).
Bottom panel. Percentage of cells displaying mitotic catastrophe (from top panel)
are plotted for control and AZD1152-HQPA treated cells. Error bars represent
95% confidence intervals.
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Figure 9
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Figure 9. Polyploidy results from treatment of Her18 breast cancer cells
with AZD1152-HQPA. A Her18 cells were treated with 100 nM AZD1152HQPA for 48 hours followed by staining with propidium iodide and FACS analysis
for cell cycle profile. Cells are gated for 2N (G1), 4N (G2/M) and 8N (polyploid)
DNA content. B Percentage 2N, 4N and 8N cells versus time from A. C Fold
increase in 8N cells from A plotted at 0, 24 and 48 hours post treatment with
AZD1152-HQPA.
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3.1.3 AZD1152-HQPA induces apoptosis and reduces tumorigenic
phenotype in breast cancer cells.

To investigate the cell death induced by AZD1152-HQPA , we evaluated
apoptosis as a possibility. Her18 cells were treated for up to 48 hours with 100
nM AZD1152-HQPA and stained with Annexin V/PI followed by analysis via
FACS for apoptotic cells. Figure 10 shows that control cells had 5.64% apoptotic
cells while the treated groups had 9.22% at 24 hours and 15.57% at 48 hours.
Lower right and upper right panels were added together for total apoptotic cell
percentage. The lower right quadrant indicates early apoptosis and the upper
right indicates late apoptosis. Similar observations were made for MB-MDA-231
cells where control showed 3.2% apoptosis while the drug treated groups
showed 12.5% and 16.4% apoptosis at 48 and 72 hours respectively (Figure 11).
Further evidence for apoptosis in AZD1152-HQPA treated cells can be seen in
Figure 12. Both Her18 and MB-MDA-231 cells treated with increasing dose of
the drug displayed cleavage of PARP (Poly [ADP-Ribose] Polymerase). Both
results agree with the IC50s for these cell lines (Figures 5 & 6) and are
confirmation that AZD1152 can kill breast cancer cells by inducing apoptosis.

Given that AZD1152 was causing apoptosis in breast cancer cells and
inhibiting their growth, it was investigated if the drug could affect the
tumorigenicity of these cell lines by colony forming and soft agar assays. Her18
cells were plated in 6-well tissue culture dishes at 5000 cells /well then treated
with 40 nM AZD1152-HQPA or vehicle. Cells were incubated for 12 days and
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colonies allowed to develop. Crystal violet staining revealed that AZD1152HQPA was able to reduce the tumorigenic phenotype by reducing the colony
number from approximately 2250 in the control, to under 500 in the treated group
(Figure 13, bottom panel). Representative plates are shown in Figure 13, top
panel. The difference in mean colony number was significant at P<0.001 by
student’s t test. To investigate the effect of AZD1152-HQPA in anchorageindependent growth of cells, Her18 cells were evaluated in a soft agar colony
formation assay. Cells were planted at low density in 3.5 cm Petri dishes with
soft agar and treated with 80 nM of drug. Control plates showed a mean of
approximately 70 colonies while the drug treatment plates showed <10 colonies.
This result was significant (P<0.001) and is furher evidence that AZD1152-HQPA
can reduce the tumorigenic phenotype observed in Her18 cells in both
anchorage-dependent and anchorage-independent environments. See
APPENDIX C for colony forming and soft agar assays is response to AZD1152HQPA in Her18 parent line, MCF7.
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Figure 10. Apoptosis is induced by AZD1152
AZD1152-HQPA
HQPA in Her18 cells. Her18
breast cancer cells were treated for up to 48 hours with 100 nM AZD1152-HQPA.
AZD1152
Cells were stained with Annexin V
V-FITC
FITC and PI followed by analysis via flow
cytometry at time 0, 24 and 48 hours.
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MDA-231 cells.
Figure 11. Apoptosis is induced by AZD1152-HQPA in MB-MDA
MB-MDA-231 breast cancer cells were treated for up to 72 hours with 100 nM
AZD1152-HQPA.
HQPA. Cells were stained with Annexin V
V-FITC
FITC and PI followed by
analysis via flow cytometry at time 0, 48 and 72 hours.
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Figure 12. AZD1152-HQPA
HQPA induces PARP cleavage in Her18 and MB-MDAMB
231 cells. Her18 and MB
MB-MDA-231
231 breast cancer cells were treated with
increasing dose of AZD1152
AZD1152-HQPA
HQPA as indicated for 48 hours. Cell lysates were
analyzed by immunoblot with anti
anti-PARP antibody. PARP appears at 115 kD and
the apoptotic indicator, cleaved PARP, appears at 85 kD.
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Figure 13
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Figure 13. Colony formation is reduced by AZD1152-HQPA. Her18 cells
were plated in 6-well tissue culture dishes at 5000 cells/well and allowed to
attach for 24 hours followed by treatment with either vehicle or 40 nM AZD1152HQPA. After 12 days, plates were stained with crystal violet and photographed,
top. Bottom panel, colonies per plate are plotted for 3 replicates. Statistical
significance was observed using the Student’ t test. Error bars: 95% CI.
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Figure 14. Anchorage
Anchorage-independent
independent colony formation is inhibited by
AZD1152-HQPA. Her18 cells were plated at 5000 cells/plate in 3.5 cm Petri
dishes in soft agar. Plates were treated with 80 nm AZD1152 and incubated for
26 days. Colonies numbers are plotted for vehicle and treatment groups as
means from 3 replicate plates. Significance of p<0.001 was observed with the
Student’s
tudent’s t test. Error bars: 95% CI.
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3.1.4 AZD1152 inhibits growth of breast cancer xenografts in vivo.

To investigate the potential for AZD1152 to inhibit the growth of
aggressive breast cancer in vivo, the use of a mammary fat pad xenograft
system was employed. 8.5 x 106 Her18 cells were injected subcutaneously into
the mammary fat pad of six to eight week old female athymic nude mice. Mice
were randomized into three groups: control (0.3 M Tris), low dose AZD1152
(62.5 mg/kg/day) and high dose AZD1152 (125 mg/kg/day). Dose of AZD1152
was based on previous reports that 10-150 mg/kg/day will produce sufficient
plasma concentration in nude mice (Mortlock et al., 2007; Wilkinson et al., 2007).
AZD1152 prodrug was used rather than the metabolized form, AZD1152-HQPA.
Tumor growth was maintained with weekly IP injections of 3 mg/kg estradiol
cypionate (estrogen analog) as described here (Jerome et al., 2006; Wang et al.,
2004). When tumors reached measureable range (approximately 50 mm3),
treatment began. AZD1152 or control were injected IP on day one and two of a
seven day repeating cycle for three weeks. Tumor volumes were estimated
every two to three days by caliper measurement and the formula: Length x
Width2 /2. Figure 15 shows the tumor volume estimates plotted for each group.
The high dose group showed significant reduction in tumor volume versus control
(P<0.001) while the low dose group showed near significant reduction (P<0.08)
in tumor volume. Figure 16, top panel, shows representative mice from the three
treatment groups bearing xenografts. After 24 days, mice were sacrificed and
tumors removed and weighed. Figure 16, bottom panel, shows the mean tumor
weight plotted for each group. Tumor mass for both low and high dose groups
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were significantly reduced compared to control (P<0.01). Tumor proteins were
extracted and analyzed by immunoblot for Aurora B activity. Figure 17 shows
that the major Aurora B substrate (Goto et al., 2002), phosphorylated Histone H3
(serine 10), which is important in Histone H1 dissociation from chromatin during
chromatin condensation (Hirota et al., 2005; Wei et al., 1999), is reduced in
AZD1152 treated tumors versus untreated controls indicating that AZD1152 was
able to reduce Aurora B kinase activity in vivo. Tumor samples from all groups
were also fixed in formalin and paraffin embedded for immunohistochemical
staining. Figure 18 top panels, show H&E staining for control and high dose
groups at high magnification. Multinucleate cells can be seen in AZD1152
treated cells (circles) and are consistent with in vitro observation of
multinucleation in Figure 8. Further immunohistochemical staining of all three
treatment groups for Ki-67 and cleaved Caspase-3 indicate that consistent with in
vitro results (Figures 5, 6 and 10), AZD1152 is able to reduce proliferation and
induce apoptosis in vivo.
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Figure 15
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Figure 15. AZD1152 prodrug inhibits growth of breast cancer cells in vivo.
Six to eight week old athymic nude mice were injected in the mammary fat pad
with 8.5 x 106 Her18 cells and randomized into 3 treatment groups: Control (0.3
M Tris), low dose (62.5 mg/kg/day) AZD1152 and high dose 125 mg/kg/day
AZD1152. All mice received weekly subcutaneous injections of estradiol
cypionate (3 mg/kg/week) to support tumor growth beginning two weeks prior to
injection with xenografts. Treatment with drug or control began when tumors
were measureable (approximately 50 mm3) and continued for 3 weeks on day 1
and 2 of a 7 day repeating cycle (indicated by horizontal bars). Tumor volumes
were measured with calipers and estimates plotted as means of each group.
Significance was determined in a mixed linear model: P<0.001. Error bars
represent standard error.
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Figure 16

75

Figure 16. Tumor mass in Her18 xenografts is reduced with AZD1152
treatment. Top panel, representative mice from control, low dose and high dose
treatment groups from Figure 15. Arrows indicate xenograft. Bottom panel,
excised tumors from control (n=6), low dose (n=8) and high dose (n=6) mice
were weighed and are shown plotted as means for each group. P values were
calculated as one-way ANOVA. Error bars represent 95% CI.
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Figure 17. AZD1152 inhibits Aurora B kinase activity in vivo. Tumor
samples from Her18 xenografted nude mice treated with control, low and high
doses of AZD1152 were lysed and proteins analyzed by immunoblot for
phospho-Histone H3.
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Figure 18
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Figure 18. Immunohistochemistry analysis of Her18 xenograft tumor
samples. Tumor samples from Her18 xenografted nude mice treated with
control, low and high doses of AZD1152 were paraffin embedded and analyzed
by Immunohistochemistry. Upper panel, H&E staining of control and high dose
samples. Red circles indicate multinucleate cells in high dose treated samples.
Lower panels, H&E, Ki-67 and cleaved Caspase-3 staining.
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3.1.5 AZD1152 inhibits metastases in breast cancer.
In the previous orthotopic xenograft assay (Figures 15-18) metastasis of
tumors in either treatment or control groups was not observed. To address
whether AZD1152 could interfere with metastases of breast cancer as well as
growth of primary tumors, a model of breast cancer with lung metastasis potential
was implemented. Six to eight week-old female athymic nu/nu mice were
injected with 2 x 106 MDA-MB-231 human breast cancer cells via tail vein. Mice
were randomly separated into two groups: control and 125 mg/kg/day AZD1152.
Treatment with vehicle or drug began two days post IV injection of breast cancer
cells. Vehicle or drug were administered IP on days 1 and 2 of a 7-day repeating
cycle for 4 weeks. Mice were sacrificed after ten weeks and the lungs removed
and weighed. Figure 19 (top) displays mean weight of lungs per mouse. Control
mice had significantly (P < 0.01, two-tailed t-test) higher lung mass than lungs in
the AZD1152 group. Further, the number of gross tumor nodules was found to
be significantly higher (P < 0.008, two-tailed t-test) in the lungs of control treated
mice versus AZD1152 treated mice (Figure 19, bottom panel). Matched lung
lobes were photographed for gross anatomic comparison from two representative
mice (Figure 20). The drug treated mouse lung lobes are clearly smaller and
display no metastatic nodules while control treated lung lobes are very large and
bear many nodules. Mouse lungs were fixed in formalin and analyzed by IHC.
H&E staining of lung tissues from AZD1152-treated mice showed reduction of
tumor burden at the microscopic level (Figure 21). These data show clearly that
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AZD1152 is effective in blocking the aggressive and highly metastatic phenotype
of MDA-MB-231 cells in vivo.
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Figure 19
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Figure 19. Lung weight and metastases are reduced by AZD1152 in a
metastatic breast cancer model. 2.0 x 106 MB-MDA-231 breast cancer cells
were injected in the tail vein of six to eight week old female athymic nude mice.
Two days post injection mice were randomized into two groups: Control (0.3 M
Tris) or drug-treated (125 mg/kg/day) AZD1152. Two days post xenograft,
control or drug were injected IP on day one and two of a seven day repeating
cycle for four cycles. After ten weeks mice were sacrificed and lungs removed
for analysis. Lung weights (top) are plotted as the means for each group.
Number of metastatic lung nodules per mouse are plotted as means for each
treatment group (bottom). P values were calculated by two-tailed t test. Error
bars: 95% CI.
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Figure 20

MB-MDA-231
231 metastatic xenograft
Figure 20. Lung lobe photographs from MB
model. Matched pairs of lung lobes of representative mice from Figure
F
19 were
photographed for comparison.
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Figure 21. IHC staining of lung tissue from MB
MB-MDA-231
231 xenografts.

H&E

staining of lungs from control and drug treated mice are shown at the same
magnification. Arrows in the control photomicrograph indicate metastatic tumor
nodules.
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3.1.6 Poly-ubiquitination and degradation of Aurora B via the
proteasome are increased by AZD1152-HQPA

It has been clearly established that AZD1152 can decrease the activity of
Aurora B kinase in cells and in animal models but whether this reduction in
activity is caused only by competition for the ATP binding pocket is unknown.
Further, whether inhibition of the kinase could somehow destabilize it has not
been previously investigated. To this end, the steady state level of Aurora B in
Her18 cells treated with both increasing exposure and increasing dose of
AZD1152-HQPA was investigated. Figure 22 shows that in both cases, the
protein level of Aurora B was reduced. Additionally, It appears that the inhibition
of the kinase activity, as measured by phospho-Histone H3, precedes the decline
in overall protein level of the kinase.

To further investigate the destabilization of Aurora B, the turnover rate in
the presence and absence of AZD1152-HQPA was investigated. Her18 cells
were treated with drug for 48 hours with an additional 4 hours in the presence of
the de novo protein synthesis inhibitor, Cycloheximide (CHX). Figure 23 (top
panel) shows by immunoblot that the turnover rate of Aurora B is indeed
increased in the presence of AZD1152-HQPA. The bands from the top panel
were measured by densitometry and the integrated optical density normalized to
the Actin control relative to time 0 plotted.

To determine if the turnover rate increase for Aurora B was due to
proteasomal degradation, MB-MDA-231 cells were treated with 105 nM
86

AZD1152-HQPA with and without the proteasome inhibitor, MG132. Figure 24
shows that the reduction in Aurora B levels caused by AZD1152-HQPA was
rescued in the presence of MG132 thereby confirming that the proteasome is
involved in the degradation.

Next, the ubiquitination of Aurora B in the presence of AZD1152-HQPA
was investigated. Her18 cells were transfected with Flag-tagged Aurora B and
HA-tagged ubiquitin plasmids. Cell lysates were immunoprecipitated with antiFlag antibody and immunoblotted with anti-HA antibody. Figure 25 shows that
poly-ubiquitinated Aurora B levels were increased in the presence of AZD1152HQPA. The control lane, without HA-ubiquitin, showed no ubiquitination and only
the IgG heavy chain. These results confirm that AZD1152-HQPA increases
degradation of Aurora B via the ubiquitin-proteasome system. To determine the
E3 ligase responsible for Aurora B ubiquitination, another ubiquitination assay
was performed. Figure 25 shows that Aurora B ubiquitination is increased by
AZD1152 and can be partially rescued by transfection with either the dominant
negative form of CDC20 or Cdh1, which are both substrate recognition subunits
of the Anaphase Promoting Complex (APC), the E3 ligase complex responsible
for the degradation of Aurora B at the onset of anaphase.

Based on the results from Figures 5 through 24, a model of the regulation
of Aurora B by AZD1152 starts to come into focus. Previous studies have shown
that AZD1152 can inhibit the activity of Aurora B which interferes with normal
mitosis but no studies have shown the consequences of this inhibition for the
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kinase itself. Here, we have shown that subsequent to inhibition of Aurora B
activity, the level of the kinase itself falls substantially. Cycloheximide assays
confirm the increase in turnover of Aurora B and an assay with the proteasome
inhibitor MG132 shows that Aurora B turnover is caused at least in part, by the
proteasome.
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Figure 22. AZD1152 reduces Aurora B protein level in steady state. Her18
cells were treated with increasing exposure time (top panel) and increasing dose
(bottom panel) of AZD1152
AZD1152-HQPA
HQPA and cell lysates analyzed by immunoblot for
Aurora B, phospho-Histone
Histone H3 and Actin.
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Figure 23. AZD1152 increases the turnover rate of Aurora B kinase. Her18
cells were cultured with and without 20 nM AZD1152
AZD1152-HQPA
HQPA for 48 hours and
then treated for up to 4 hours with cycloheximide. Top, lysates were analyzed by
immunoblot for Aurora B and Actin. Bottom, turnover rate of Aurora B from the
top panel, is plotted for treated and untreated groups. Plots are the amounts of
Aurora B relative to time 0 and are corrected for loading with Actin.
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Figure 24
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Figure 24. Aurora B degradation via the ubiquitin-proteasome system is
increased by AZD1152. MB-MDA-231 cells were treated with 105 nM
AZD1152-HQPA for 48 hours in the presence and absence of the proteasome
inhibitor MG132. Lysates were immunoblotted for Aurora B and Actin.
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Figure 25. AZD1152 mediated degradation of Aurora B is through the
Anaphase Promoting Complex (APC). Her18 cells were co-transfected
transfected with
Flag tagged Aurora B, HA
HA-Ubiquitin
Ubiquitin and either the dominant negative form of
Cdh1 or CDC20 followed by treatment for 24 hours with 20 nM AZD1152 and the
proteasome inhibitor, MG132. Cell lysates were immunoprecipitated with antiFLAG antibody and immunoblotted with anti
anti-HA antibody.
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3.1.7 Inhibition of Aurora B with AZD1152 in human xenografts,
increases p53 level.

Upon staining of the Her18 xenografted tumor samples in mice (Figures
15-18), a surprising result was observed. p53 levels had increased dramatically
with dose increase of AZD1152 treatment (Figure 26). This observation could be
explained in a number of ways since p53 has many sensor pathways that could
cause its activation when major perturbations of the genome are occurring as a
result of AZD1152. However, the elevations in p53 level could also be explained
by a direct interaction of p53 and Aurora B. In the Introduction section of this
thesis the phosphorylation of p53 by Aurora A kinase was described. p53
phosphorylation by its close cousin, Aurora B could also be occurring. Thus, with
inhibition of Aurora B by AZD1152, any possible negative regulation would be
released, and p53 levels would increase. The next section of this thesis focuses
on investigation of an Aurora B-p53 interaction and its consequences for p53
level, expression, transcriptional activity and cellular function.
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Figure 26. p53 is induced in Her18 xenografts by AZD1152. Her18 xenograft
tumor samples (Figure 18) IHC stained for p53 in vehicle, low dose and high
dose AZD1152 treatment groups.
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3.2 Aurora B downregulates p53 via phosphorylation in the DNA binding
domain.

3.2.1 Aurora B and p53 interact in vitro.
In our previous findings we showed that the Aurora B kinase inhibitor AZD1152
reduced the steady state levels of Aurora B and that this was concurrent with
elevation of p53 levels in the cell. From this we can hypothesize that Aurora B
interacts directly with and phosphorylates p53. The first step in proving this
hypothesis is to show that Aurora B does associate with p53. To investigate this,
a reciprocal co-immunoprecipitation in 293T cells was performed. Figure 27
clearly shows that when Aurora B is IP’d, p53 can be detected, and also the
reciprocal. Next, it was determined if the interaction of p53 and Aurora B was
direct, by performing an in vitro pull down assay. Figure 28 shows that
recombinantly produced Aurora B and p53 do associate in vitro.

To determine where Aurora B binds to p53, another in vitro pull down
assay using GST or GST-p53 deletion constructs (Figure 41) was performed
(Figure 29). From this result, it can be seen that Aurora B binds to both the DNA
binding domain and the C-terminus of p53, hinting at the possibility that the
phosphorylation sites for Aurora B could be in the DNA binding domain or close
to the C-terminus, as they are for Aurora A.

To understand if the interaction of Aurora B and p53 is cell cycle regulated
we synchronized Hct116 cells to S-phase with a double thymidine block. Cells
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were released and analyzed every two hours by PI staining and FACS to
determine DNA content (Figure 30). Lysates were then immunoprecipitated for
Aurora B and immunoblotted for p53. Figure 31 shows that although Aurora B
and p53 are present during the whole cell cycle, they only interact during Late S
and G2/M phases with a significant drop in their interaction at some point in or
just after Mitosis. This corresponds to the reduction seen in Aurora B during
mitosis and which is known to be mediated by Anaphase Promoting Complex
(APC) in late mitosis.

To determine in which cellular compartment these two proteins interact, a
co-localization experiment was performed. Her18 cells were immunostained for
endogenous p53 and Aurora B and labeled with secondary antibodies
conjugated to Alexa-fluor fluorophores. Since the previous synchronization
experiment showed interaction during mitosis, this experiment focused on
mitosis. Figure 32 shows that Aurora B is present in late mitosis and shows its
typical localization to the midbody while p53 has a diffuse presence in the entire
cytoplasm (nuclear envelope not present). It can be said that p53 and Aurora B
are co-localizing during mitosis since the merge image shows a yellow color,
however, the staining of p53 is not exclusive to the area of staining for Aurora B.

3.2.2 Aurora B and p53 interact during interphase and mitosis.
To determine if the co-localization of Aurora B and p53 described in the
last section is real and relevant, a Venus fusion protein system was employed.
Figure 33 shows a schematic diagram of this system. The C-terminal end of the
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Venus protein (a YFP variant of GFP) is fused to one of the proteins of interest
by inserting the cDNA for that protein into the Venus C-term plasmid. The cDNA
of the other protein of interest is inserted into the Venus N-term plasmid and both
plasmids co-transfected. If the two proteins of interest interact, there is green
fluorescence. This process was performed for Aurora B and p53 by inserting
their cDNA into Venus plasmids and again in the reverse. The resulting green
fluorescence was observed in both the nucleus and cytoplasm of interphase
U2OS cells (Figure 34) but not in cells transfected with two empty or one empty
and one complete fusion plasmid (Figure 37).
To verify the previous co-localization in mitosis, 293T cells were cotransfected followed by synchronization to prophase with a thymidine-nocodazole
block. Figure 35 displays the resulting image of Aurora B-p53 interaction (green)
on the condensing chromosomes (Red, RFP-H2B). The interaction localizes to
specific points on the DNA which may be the centromeres, a known locale for
Aurora B. Figure 34B confirms this in MCF7 cells where the interaction of Aurora
B and p53 can be seen in several prophase nuclei localizing to the condensed
chromosomes stained by DAPI. An enlargement of a nuclei synchronized to
mitosis with a thymidine-nocodazole block is shown in Figure 34C. Several
outlying condensed chromosomes can be seen with green fluorescence (Venus)
at a distinct point (arrows), which is likely the centromere. Confirmation of the
Venus interaction at the centromere is shown in Figure 34C, bottom panel, where
293T cells were synchronized to prophase as before and fluorescence imaged
for Venus and Survivin, another member of the CPC. The merge image confirms
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that the interaction of p53 and Aurora B is occurring at least partially, at the
centromere.

To verify that the observed interaction was not cell-specific, Hct116 cells
were also transfected with the Venus plasmids containing Aurora B and p53.
Consistent with 293T, localization of interaction was throughout the cells (Figure
36).
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Figure 27. Aurora B and p53 exist in complex. Lysates of 293T cells were
immunoprecipitated for endogenous proteins with either anti-Aurora
urora B or anti-p53
anti
antibodies followed by reciprocal immunoblot. Lysates were also IP’d with rabbit
IgG as a control.
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Figure 28
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Figure 28. Aurora B and p53 interact directly. In vitro translated Aurora B
was incubated overnight with recombinantly produced GST or GST-p53 fusion
proteins. GST was pulled down with GST beads and precipitates were
immunoblotted with anti-Aurora B antibody. GST inputs were analyzed by SDSPAGE and Coomassie staining. Recombinant Aurora B inputs were
immunoblotted directly with anti-Aurora B antibody.
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Figure 29.
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Figure 29. Aurora B binds both the DNA binding domain and C-terminus of
p53. Flag-Aurora B plasmid was transfected into 293T cells and lysates
immunoprecipitated with anti-Aurora B antibody. IP’d Aurora B was incubated
overnight with GST, GST-p53 or GST-p53 deletion constructs that were
produced recombinantly in E. coli. GST beads were used to pull down GST and
lysates then immunoblotted with anti-Aurora B antibody. Aurora B inputs were
analyzed by immunoblot and GST-fusion protein inputs by SDS-PAGE followed
by Coomassie stain. * indicates GST-tagged proteins.
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double-thymidine
thymidine block. Hct116
Figure 30. Hct116 cells synchronized with double
cells were synchronized to S
S-phase with a double-thymidine
thymidine block then released.
At two hour intervals, cells were collected and stained with propidium iodide. Cell
cycle analysis was done by flow cytometry. Cell cycle phase is indicated at right.
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Figure 31. Aurora B and p53 interact during late S and G2/M phases of the
cell cycle. Hct116 cell lysates from Figure 30 were immunoblotted for p53,
Aurora B, phospho-Histone H3 and Cyclins D, E, A and B1. Lysates were also
immunoprecipitated for Aurora B and analyzed by immunoblot for p53 and
Aurora B. Hours post release and cell cycle phase are indicated above.
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Figure 32
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Figure 32. Endogenous p53 and Aurora B colocalize during mitosis. Her18
cells planted in chamber slides were fixed and immunostained for endogenous
p53 and Aurora B as well as stained with DAPI. Alexa-fluor 488 and 568
conjugated secondary antibodies were used in the immunostaining.
Photomicrographs of cells in anaphase and telophase are shown. Colocalization is displayed as yellow color in the merge image.
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Figure 33. Schematic diagram of the Venus fusion protein system. The
Venus (YFP variant) fusion protein interaction system works by inserting the
cDNA of a protein of interest in a plasmid containing each half of the Venus
protein. Plasmids are then co-transfected and any interaction is observed by
fluorescence microscopy.
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Figure 34A
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Figure 34B
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Figure 34C
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Figure 34. Aurora B and p53 interact directly in both the cytoplasm and
nucleus during interphase and mitosis. A Venus N-terminal-Aurora B and
Venus C-terminal-p53 plasmids (and the reverse combination) were cotransfected into U2OS cells. Cells were fixed, stained with DAPI and imaged by
fluorescence microscopy. Direct interaction of p53 and Aurora B is indicated by
green fluorescence. B MCF7 cells were transfected as in A as indicated and
synchronized to mitosis using a thymidine-nocodazole block. Scale bar = 10 µm.
C Top panel, enlargement of an MCF7 nuclei synchronized as in B to mitosis.
Arrows indicate condensed chromosomes with green staining (Venus) at the
centromere. Scale bar = 4 µm. Bottom panel, 293T nuclei synchronized to
prophase with thymidine-nocodazole block as in B. Immunofluorescence
staining for DAPI, Venus (interaction of Aurora B and p53 as in A) Survivin and
merge image for red and green channels are shown.

113

Figure 35
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Figure 35. p53 and Aurora B interaction occurs on the DNA during mitosis.
293T cells were transfected with the indicated Venus fusion plasmids and RFPH2B. Cells were synchronized to prophase with nocodazole and live-imaged by
spinning-disk confocal microscopy. Red indicates H2B (DNA) and green
indicates direct interaction of Aurora B and p53.
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Figure 36. The association between p53 and Aurora B is also present in
Hct116 cells. Hct116 cells were transfected with the indicated empty Venus
(control) or Venus fusion plasmids and live
live-imaged
imaged by fluorescence microscopy
and phase contrast.
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Figure 37. Venus fusion system showing Aurora B and p53 direct
colocalization control
controls. U2OS cells were co-transfected
transfected with the indicated
control plasmids or Venus fusion plasmids
plasmids.. Cells were fixed, stained with DAPI
and imaged via confocal fluorescence microscopy.
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3.2.3 Aurora B phosphorylates p53.
Having established that p53 and Aurora B interact directly, investigation of
p53 phosphorylation by Aurora B was the logical next step because of Aurora B’s
kinase activity. To do this, Aurora B immunoprecipitated by 293T cells was
incubated with GST or GST-p53 in the presence of 32P labeled ATP in an in vitro
kinase assay (Figure 38). Aurora B was found to phosphorylate GST-p53
strongly compared to control substrate GST. Kinase reactions where no Aurora
B was added did not show p53 phosphorylation.
Once it was established that IP purified Aurora B phosphorylated p53,
determination that this was due to Aurora B kinase activity, and not by a
contaminating kinase was necessary. This was accomplished through an in vitro
kinase assay as before but using IP purified wild type Aurora B or kinase dead
Aurora B where lysine 106 was replaced with an arginine (Chen et al., 2003).
See Table 5 for primer sequences. Figure 39 shows that wild type Aurora B and
not kinase dead Aurora B phosphorylated GST-p53.

Since it was observed in previous results that AZD1152 reduced Aurora B
activity and induced p53 level when used in xenografts of breast cancer cells,
AZD1152 should be able to reduce the ability of Aurora B to phosphorylate p53.
To investigate this, an in vitro kinase assay was performed as before but in the
presence of increasing dose of AZD1152. Figure 40 clearly shows that 50 nM
AZD1152-HQPA inhibited phosphorylation of p53 as well as Aurora B
autophosphorylation.
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Figure 38

119

Figure 38. Aurora B phosphorylates p53 in vitro. Immunoprecipitated FlagAurora B was incubated with GST or GST-p53 substrates in the presence of 32P
ATP. Phosphorylated substrates were detected with a phosphoimager. Aurora
B inputs were analyzed by immunoblot and GST-tagged substrates by SDSPAGE and Coomassie staining.
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Figure 39. Aurora B but not kinase dead Aurora B phosphorylates p53.
Immunoprecipitated Flag-Aurora B or Flag-Aurora B K106R (kinase dead) were
incubated with GST-p53 in an in vitro kinase assay as in Figure 38. Aurora B
and GST-tagged inputs were analyzed by immunoblot.
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Figure 40. Aurora B mediated phosphorylation of p53 is inhibited by
AZD1152-HQPA. Recombinant GST-Aurora B was used in an in vitro kinase
assay with GST-p53 substrate, as in Figure 38, with increasing dose of
AZD1152-HQPA. p53 input was analyzed by SDS-PAGE and Coomassie stain.
Recombinant GST-Aurora B input was analyzed by immunoblot for Aurora B.
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3.2.4 Aurora B phosphorylates multiple serine/threonine residues in
the DNA binding domain of p53.

The next step in further characterizing the phosphorylation of p53 by
Aurora B, is to determine where the phosphorylation is occurring. To address
this, an in vitro kinase assay was performed in which p53 deletion constructs
(Figure 41) were used as substrates for Aurora B. Figure 42 shows that Aurora
B phosphorylates p53 only in the wild type and the 160-393 construct (indicated
by *), while it does not phosphorylate the 320-393 region. This indicates that the
phosphorylation occurs between residues 160-320 roughly corresponding to the
DNA binding domain of p53. This result is consistent with the in vitro binding
data in Figure 28 where Aurora B was found to bind the DNA binding domain. A
multiple alignment of the p53 DNA binding domain of higher eucaryotes is
displayed in Figure 43 and shows that there are five possible phosphorylation
sites for Aurora B kinase that match the consensus phosphorylation sequence:
(R/K)1.3X(S/T). Further, four of the five sites are fully conserved from Zebra fish
to humans with the exception of S183 which is not conserved in Zebra fish only.
The evolutionary conservation of these sites lends weight to their importance in
the regulation of p53. Figure 44 displays the Netphos scores indicating likely
phosphorylation by potential kinases for each of the five sites (Blom et al., 1999).
To determine which of the five putative sites in p53’s DNA binding domain were
phosphorylated, another in vitro kinase assay was performed where GST-p53
was mutated in each of the sites to an alanine residue. Recombinant Aurora B
was used to phosphorylate each of these mutants as well as wild type p53 and
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phosphosubstrates were analyzed for comparison. Figure 45 shows that at least
four of the five sites were phosphorylated with S215 being the strongest and
T284 not phosphorylated at all. S183, T211 and S269 were also phosphorylated
and are listed in order of strength. An alternative interpretation is also possibly.
S215 may be the major phosphorylation site with the other sites being required
for association of the kinase with p53.
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Figure 41. GST-tagged
tagged p53 deletion constructs.
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Figure 42

126

Figure 42. Aurora B phosphorylates p53 in the DNA binding domain.
Recombinant Aurora B was incubated with GST, GST-p53 or GST-p53 deletion
constructs as substrates in an in vitro kinase assay.
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P labeled substrates were

detected with a phosphoimager. GST-tagged substrate inputs are shown as
Coomassie stained bands, recombinant Aurora B input was analyzed via
immunoblot. * indicates phosphorylated GST-p53 (160-393).
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Figure 43. Putative Aurora B phosphorylation sites in the p53 DNA binding
domain. Multiple alignment of the p53 DNA binding domain of higher eukaryote
species with five putative Aurora B phosphorylation sites shown. Conserved
residues are shown in red.
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Figure 44. Putative Aurora B phosphorylation residues in p53 and their
Netphos scores.
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Figure 45. Aurora B phosphorylates four serine/threonine residues in the
p53 DNA binding domain. GST-tagged p53 was mutated to contain five
separate alanine mutations in the DNA binding domain: S183A, T211A, S215A,
S269A and T284A. Wild type and mutated GST substrates were incubated with
recombinant Aurora B kinase in an in vitro kinase assay. Phosphorylated
substrate and Aurora B autophosphorylation were detected with a
phosphoimager. GST-p53 substrate inputs were detected by Coomassie stain,
Aurora B input was detected by immunoblot.
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3.2.5 Aurora B destabilizes p53 via the ubiquitination-proteasome
system.

Functional relevance of the phosphorylation of p53 by Aurora B was the
next thing investigated in this study. First, the focus was put on whether Aurora
B can affect p53 stability or expression. Figure 46 focuses on the steady state
level of p53 when Aurora B is overexpressed in increasing dose. The results
show that as Aurora B level increased, p53 levels dropped, indicating that Aurora
B can effect a change in p53 steady state level. To determine if Aurora B could
alter the turnover rate of p53, Flag-Aurora B was transfected into U2OS cells in
the presence of cycloheximide (CHX). As Figure 47 shows (top), p53 was
degraded faster in the presence of Aurora B versus the control, where no Aurora
B was present. To confirm that this result was happening not only in an
overexpression system, but also in endogenous p53 levels, 293T cells were
infected with lentiviruses containing either control (shRNA luciferase) or Aurora B
knockdown shRNA (shRNA 468 AurB), again in the presence of CHX. The result
shows that when Aurora B was knocked down, p53 turnover was reduced (Figure
47, bottom panel). These assays confirm that Aurora B affects p53 protein level
in both overexpressed and endogenous proteins.

To determine if the increased turnover of p53 observed in the presence of
Aurora B is due to proteasomal degradation, p53 null H1299 cells were
transfected with GFP-p53 and Flag-Aurora B in the presence of MG341
(Velcade), a proteasome inhibitor. Indeed, MG341 was able to rescue the p53
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protein level in the presence of overexpressed Aurora B indicating that Aurora B
is mediating the degradation of p53 via the proteasome (Figure 48).

Proteasomal degradation of p53 mediated by ubiquitination of p53 was
investigated by performing an ubiquitination assay. 293T cells were transfected
with p53, Mdm2 and HA-ubiquitin as indicated in Figure 49. 24 hours prior to
harvest, cells were treated with increasing dose of AZD1152-HQPA. Cells were
also treated with MG132 five hours prior to harvest. At harvest, cell lysates were
immunoprecipitated with anti-HA antibody to isolate ubiquitinated proteins.
Ubiquitinated p53 was detected via immunoblot. Figure 49 (top panel) shows
that the basal level of p53 ubiquitination in cells was decreased in a dose
dependent fashion by the addition of AZD1152-HQPA. This indicates that
inhibition of Aurora B increases p53 ubiquitination and agrees with the results in
Figure 48 that Aurora B mediates the breakdown of p53 via the proteasome. Of
note is that the dosage of AZD1152-HQPA was in the nanomolar range, which is
relevant to the IC50s reported for several cell lines in Figures 5 and 6. The
bottom panel of Figure 49 also shows that the ubiquitination of p53 is increased
by Aurora B with the overexpression of Aurora B itself, and also confirms that
Mdm2 is at least partially responsible for the ubiquitination mediated by Aurora B.

It is a possibility that Aurora B could also be affecting the expression level
of p53 by regulating genes upstream of p53 or p53 mRNA levels directly. To rule
this out, U2OS and Hct116 cells were transfected with Aurora B. mRNA levels of
p53 and several p53 target genes were measured by qRT-PCR. In both cases,
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p53 mRNA was not affected, however, mRNA levels of p53 target genes Mdm2,
p21 and BAX all show reduced levels in the presence of Aurora B (Figure 50).
This is confirmation that p53 level is reduced post-translationally by Aurora B and
p53 then has a reduced capacity to affected the expression of its target genes.
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Figure 46. Aurora B reduces p53 steady state level. GFP-p53 and an
increasing dose of Flag-Aurora B were transfected in p53 null H1299 cells as
indicated. p53, Flag-Aurora B and Actin were detected by immunoblot.
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Figure 47

135

Figure 47. Aurora B increases the turnover rate of p53. Top, U2OS cells
were transfected with and without Flag-Aurora B and treated with cycloheximide
2 hours prior to harvest. p53, Flag-Aurora B and Actin were analyzed by
immunoblot. Bottom, 293T cells were infected with lentiviruses containing control
shRNA-luc. or shRNA 468 AurB. Cells were treated with cycloheximide two
hours prior to harvest and lysates analyzed by immunoblot for endogenous p53,
Aurora B and Actin. * indicates a non-specific band.
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Figure 48. Aurora B mediates turnover of p53 via the proteasome. p53 null
H1299 cells were transfected with GFP-p53 and Flag-Aurora B as indicated then
treated with MG341 (Velcade), a proteasome inhibitor, for 24 hours prior to
harvest. Cell lysates were analyzed by immunoblot for GFP-p53, Flag-Aurora B
and Tubulin.
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Figure 49

138

Figure 49. Mdm2 ubiquitination of p53 is increased by Aurora B. Top panel,
293T cells were transfected with p53, Mdm2 and HA-ubiquitin plasmids as
indicated. AZD1152-HQPA was applied 24 hours prior to harvest. Five hours
prior to harvest, cells were treated with MG132 to accumulate ubiquitinated
proteins. Cell lysates were immunoprecipitated with anti-HA antibody and
immunoblotted for p53. Bottom Panel, plasmids were transfected as indicated
and lysates immunoprecipitated with anti-HA antibody. Ubiquitinated p53 was
detected by immunoblot with anti-GFP antibody.

139

Figure 50
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Figure 50. Aurora B affects p53 at the post-transcriptional level. U2OS
(top) and Hct116 (bottom) cells were transfected with vector control or FlagAurora B kinase and analyzed by qRT-PCR for p53 or p53 target mRNA levels.
Error Bars: 95% CI.
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3.2.6 p53 transcriptional activity and oligomerization are decreased
by Aurora B.

It has been established that the phosphorylation of p53 by Aurora B
destabilizes p53 and leads to its degradation via the ubiquitin proteasome
system. This should also cause p53 transcriptional activity to be decreased by
Aurora B. To investigate this, a dual luciferase reporter system was used in
which a p53 reporter luciferase plasmid containing the p53 response elements
from the 14-3-3σ promoter were inserted upstream of the firefly luciferase gene.
A second luciferase plasmid, Renilla luciferase, is used as a transfection control.
In addition to the luciferase reporters, GFP-p53 and increasing dose of GFPAurora B plasmids were transfected into 293T cells. p53 transcriptional activity
was measured with a luminometer. Figure 51 shows that as Aurora B increased,
p53 transcriptional activity dropped. This was confirmed by another luciferase
assay where Aurora B was silenced using transfection of an shRNA plasmid
(Figure 52, top). Figure 52, bottom panel, shows that as the dose of shRNA 468AurB plasmid increased, p53 transcriptional activity increased. Together these
results indicate that Aurora B can reduce the ability of p53 to bind the p53
response elements in the 14-3-3σ promoter and turn on transcription.

In a further confirmation of the effect of Aurora B on p53 transcriptional
activity, a p53 oligomerization assay was performed in the presence of either
Flag-Aurora B or the kinase dead Flag-Aurora B K106R. To detect p53
oligomers, cell lysates were treated for 15 minutes with 0.01% glutaraldehyde.
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Figure 53 depicts the p53 immunoblot analysis of these cell lysates and shows
that in the presence of Aurora B, p53 oligomerization is eliminate,d while K106R
Aurora B cannot completely eliminate oligomers. These results confirm and add
another layer of regulation to the previous evidence that Aurora B can reduce
p53 transcriptional acitivity.
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Figure 51. Overexpression of Aurora B decreases p53 transcriptional
activity. 293T cells were transfected with GFP
GFP-p53
p53 and increasing dose of GFPGFP
Aurora B. p53
53 transcriptional activity was measured with a dual luciferase
reporter system using a p53 luciferase repo
reporter (14-3-3σ promoter) and Renilla
luciferase. Baseline p53 transcription was set at 1, error bars are 95%
confidence intervals.
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Figure 52
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Figure 52. Knockdown of Aurora B increases p53 transcriptional activity.
Top panel, 293T cells infected with lentivirus controls, shRNA-GFP or shRNA
luciferase, and lentivirus knockdowns of Aurora B, shRNA 468-AurB or shRNA
1185-AurB. Knockdown of Aurora B was detected by immunoblot. Bottom
panel, 293T cells were transfected with GFP-p53 and increasing dose of shRNA
468-AurB plasmid. p53 transcriptional activity was measured as in Figure 51.
Error bars: 95% CI.
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Figure 53. p53 oligomerization is decreased by Aurora B mediated
phosphorylation. H1299 cells were transfected with p53 and Flag-Aurora B or
Flag-Aurora B K106R with 0.01% glutaraldehyde. p53 oligomers were detected
by immunoblot.
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3.2.7 Phosphorylation of threonine 211 in p53’s DNA binding domain
reduces transcriptional activity and increases turnover.

To determine the functional relevance of the Aurora B phosphorylation
sites in p53’s DNA binding domain, three of these sites were mutated to alanine,
which cannot be phosphorylated, and several functional assays carried out. First
a luciferase assay was performed to determine which phosphorylation site(s) is
important for p53 transcriptional activity. Figure 54 shows the result of this assay
where p53 null H1299 cells were transfected with and without Aurora B and
various p53 constructs. Control transfection luciferase activity was set at 1
(horizontal bar) and reduction of p53 transcription by Aurora B compared relative
to this. By this result, Aurora B expression was able to reduce p53 transcription
in all but the threonine 211 mutant. This is corroborated by the inclusion of a
triple A mutant in which S183, T211 and S215 were all mutated. It can be seen
clearly that Aurora B does not efficiently reduce the transcription of this mutant as
well.

Next, the turnover rate of the phosphorylation mutants in the presence of
Aurora B was determined. p53 null H1299 cells were transfected with either
GFP-p53 or GFP-p53 AAA mutant (S183A, T211A, S215A) in the presence of
either Flag-Aurora B or Flag-Aurora B K106R mutant. Two hours prior to
harvest, cells were treated with cycloheximide. The turnover rate for p53 was
determined by immunoblot (Figure 55). The results show that wild type Aurora B
cannot increase the turnover of p53 AAA mutant compared to wild type p53.
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Further, kinase dead Aurora B K106R could not turnover wild type p53 as
efficiently as wild type Aurora B indicating that the turnover of p53 is mediated by
the kinase activity of Aurora B.

To determine if mutation of these DNA binding domain sites could affect
the mRNA levels of p53 targets, qRT-PCR was performed for the mRNA levels of
p21. Hct116 p53 -/- (Figure 56, top panel) or p53 null H1299 cells (Figure 56,
bottom panel) were transfected with Flag-Aurora B and either GFP-p53 or GFPp53 AAA mutant. The result here shows that Aurora B could not efficiently
reduce p21 mRNA levels when using the p53 AAA mutant versus the wild type
control in both cell lines. The difference in reduction was statistically significant
in both cases.

In summary, Figures 54-56 show clearly that mutation of S183, T211 and
S215 to alanine, reduces the capacity of Aurora B to inhibit p53 transcriptional
activity and mediate its turnover. This demonstrates that one or all of these
phosphorylation sites are important in regulation of p53 by Aurora B.
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Figure 54. Aurora B reduces p53 transcriptional activity by
phosphorylating threonine 211 in p53’s DNA binding domain. p53 null
H1299 cells were transfected with dual luciferase reporters, Aurora B and p53
phosphorylation site alanine mutants. Luciferase activity was measured by
luminometer and results plotted relative to control (no Aurora B transfection,
horizontal bar). Datapoints represent 3 replicates, error bars: 95% CI.
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Figure 55. Phosphorylation site mutants are stabilized in the presence of
Aurora B. p53 null H1299 cells were transfected with either GFP-p53 or GFPp53 AAA mutant (S183A, T211A, S215A) in the presence of either Flag-Aurora B
or Flag-Aurora B K106R mutant. Two hours prior to harvest, cells were treated
with cycloheximide. Lysates were immunoblotted for GFP to determine p53
turnover rate.
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Figure 56
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Figure 56. p21 mRNA is not efficiently reduced by Aurora B in the
presence of the p53 AAA mutant. Hct116 p53 -/- (top panel) or p53 null H1299
cells (bottom panel) were transfected with Flag-Aurora B and either GFP-p53 or
GFP-p53 AAA mutant. qRT-PCR was performed to determine p21 mRNA levels.
* indicates P<0.05 with a student’s t test. Error bars: 95% CI.

153

3.2.8 Inhibition of Aurora B stabilizes p53 and increases p53 target
genes in tumors and tissue culture.
To assess the in vitro and in vivo effect that the inhibition of Aurora B may
cause in tumors or tumor cells, thorough evaluation of p53 and p53 target genes
was performed. Her18 xenograft tumors from nude mice (Figures 15-18, 26)
were analyzed by immunohistochemistry for p53 in tumors from the three
treatment groups: Vehicle, low dose (62.5 mg/kg/day) and high dose (125
mg/kg/day) AZD1152. Figure 26 showed clearly that p53 staining was increased
in both drug treated groups. Figure 57 shows quantification of the measurement
of percent positive p53 and intensity of staining on these slides. In both drug
treated groups percent positive and intensity of p53 staining was significantly
increased versus control indicating that inhibition of Aurora B in vivo stabilizes
p53 effectively.
As confirmation that p53 is stabilized by Aurora B inhibition in vivo, tumor
proteins were extracted after snap-freezing of tumor tissues and analyzed for p53
and p53 target protein levels. Figure 58 shows that in three representative
tumors with use of AZD1152, p53 and p53 target genes Mdm2, Bax and Puma
were all increased versus the control. To confirm this in tissue culture, Her18
cells were treated for 48 hours with an increasing dose of AZD1152-HQPA and
p53 and its targets analyzed by immunoblot. Figure 59 shows clearly that as in
the case of tumor cells, tissue culture also responds the same way and p53 and
its target protein levels all increase with dose of AZD1152-HQPA.
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Figure 57. AZD1152 increases p53 level in Her18 human xenografts. Top,
Human Her18 xenograft tumors from Figure 26 were scanned for p53 positive
cells and are plotted at percentage for vehicle,
ehicle, low dose (62.5 mg/kg/day) and
high dose (125 mg/kg/day) AZD1152. Bottom, p53 intensity was scanned and
plotted for 3 treatment groups as before. * P<0.05. Error bars: 95% CI.
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Figure 58. p53 and p53 targets are induced in vivo by AZD1152. Three
representative mice bearing Her18 xenograft tumors (from Figure 26) were
selected from each treatment group (vehicle, low and high dose AZD1152) and
tumor proteins extracted. Lysates were immunoblotted for p53 and the p53
targets: Mdm2, Bax and Puma.
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Figure 59. AZD1152-HQPA stabilizes p53 and induces p53 targets in vitro.
Her18 cells were treated for 48 hours with an increasing dose of AZD1152-HQPA
up to 80 nM. Cell lysates were immunoblotted for p53 and the p53 target genes:
Mdm2, p21 and 14-3-3σ. Aurora B activity was assessed by immunoblot for
phospho-Histone H3.
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3.2.9 Aurora B reduces p53 mediated apoptosis.

Previously it was shown that Aurora B could reduce p53 level and
downregulate its transcriptional activity. To determine if Aurora B could have an
effect on p53’s overall function, an apoptosis assay was performed. Hct116 cells
were transfected with Flag-Aurora B and treated with 20 µM Cisplatin to induce
DNA damage and induce the p53 DNA damage response. To measure this
response, p53 mediated apoptosis was assayed by propidium iodide staining and
sub G1 cell population determined. Figure 60 shows the result of sub G1
analysis from three replicates. In Cisplatin treated cells, Aurora B was able to
reduce sub G1 cells significantly while no reduction was observed in non-treated
cells. Representative individual flow cytometry histograms are shown in Figure
61. This data proves conclusively that Aurora B can affect p53’s apoptotic
function when induced by a DNA damage agent.

158

Figure 60. Aurora B reduces p53 mediated apoptosis. Hct116 cells were
transfected with Flag-Aurora
Aurora B followed by treatment with 20 µM
M Cisplatin
(CDDP) for 24 hours. Percentage Sub G1 cells were determined by propidium
iodide staining and flow cytometry analysis. * P<0.05 by Student’s
tudent’s t test. Error
Bar: 95% CI.
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Figure 61. Aurora B reduces p53 mediated apoptosis – representative
samples. Representative Hct116 samples from Figure 60. Gating: Sub G1
cells.
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Chapter 4. Discussion
The data outlined in this thesis show that inhibition of Aurora B kinase by
the specific inhibitor, AZD1152, is sufficient to reduce breast cancer cell growth
and may indicate clinical relevance in the treatment of breast cancer. Inhibition
of Aurora B was also shown to increase p53 levels in the cell, hinting at a
previously unknown negative regulation of p53 by Aurora B. Indeed, it was
shown that Aurora B phosphorylates p53 in the DNA binding domain and
decreases p53 transcriptional activity. This relationship is of special interest, not
only because of the importance of p53 as the genome guardian or because of
Aurora B’s oncogenic status in many cancer types, but because the function of
p53 and Aurora B were previously thought to be temporally exclusive during the
cell cycle.
This exclusivity revolves around the fact that Aurora B is thought to have
function only during mitosis and that p53 has been presumed to have function
outside mitosis, due to shutdown of global transcription during cell division.
These data show that p53 and Aurora B interact in both interphase and mitotic
phases of the cell cycle, indicating that an important new function for both
proteins may be present.

The major findings of this thesis are that inhibition of Aurora B kinase has
significant impact on breast cancer tumorigenesis and brings to light a previously
unknown pathway for the regulation of p53 by mitotic kinase Aurora B. In several
previous studies, it was shown that AZD1152 was able to specifically inhibit the
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kinase activity of Aurora B and kill several cancer cell types. This study adds
breast cancer to the list of cancers in which AZD1152 is shown to be effective via
inhibition of Aurora B kinase. The data clearly shows that AZD1152 inhibits the
growth of breast cancer cells regardless of Her2 status (Figures 6, 7, APPENDIX
A), can cause mitotic catastrophe (Figure 8) with subsequent apoptosis (Figures
10, 11) and can decrease the tumorigenicity of breast cancer cells (Figures 13,
14, APPENDIX C). AZD1152 was also shown effective in reducing both tumor
growth and tumor weight in orthotopic and metastatic xenograft murine models of
human breast cancer (Figures 15, 16, 19, 20).
Upon investigation of the outcome for Aurora B kinase in the presence of
AZD1152, this study found that protein levels of Aurora B were reduced, and that
ubiquitination of Aurora B was increased via the Anaphase Promoting Complex
(Figures 22-25). Figure 62 displays a model for these observations. The left
pathway was described previously in several reports which showed that
AZD1152 inhibits Aurora B activity, as measured by phosphorylated Histone H3.
This leads to aberrant and reduced mitosis (Evans et al., 2008; Wilkinson et al.,
2007; Yang et al., 2007). These observations are confirmed by the present study
in breast cancer. The right model shows the proposed pathway that AZD1152
can also lead to ubiquitination of Aurora B by the APC complex and leads to its
subsequent degradation. This, in turn, also led to mitotic blockade or aberrant
mitosis.
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As a consequence of inhibition of Aurora B by AZD1152, p53 levels were
increased in two xenograft murine models (Figure 26). This hinted at a possible
direct interaction between p53 and Aurora B. Indeed, it was found that p53 and
Aurora B exist in complex and interact directly in a cell cycle dependent fashion
(Figures 27-31). Further, Aurora B was shown to phosphorylate p53 at several
serine/threonine residues in the DNA binding domain and that these events
caused downregulation of p53 levels via ubiquitination mediated by Mdm2
(Figures 38-42, 49). Phosphorylation of T211 was shown to reduce p53’s
transcriptional activity while phosphorylation at S183 or S215 was unable to do
this (Figure 54). Inhibition of Aurora B was also shown to increase p53 levels in
tumors and in tissue culture which led to increased levels of p53 target genes
(Figures 57, 58). Functionally, Aurora B was shown to reduce p53’s capacity to
mediate apoptosis in response to the DNA damaging agent, cisplatin (Figures 60,
61).
Figure 63 outlines the proposed regulation of p53 by Aurora B and shows
that Aurora B can phosphorylate the p53 DNA binding domain, which results in
the degradation of p53 and reduction of p53’s transcriptional function.
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Figure 62. Model of regulation of Aurora B kinase by AZD1152. AZD1152 is
known to negatively impact Aurora B activity by reducing phospho-HH3
phospho
levels.
Reduced p-HH3
HH3 levels block chromatin condensation and thereby inhibit mitosis.
New data from this study shows that AZD1152 also increases Aurora B
ubiquitination and destabilizes Aurora B leading to activation of the spindle
assembly checkpoint and mitotic blockade thereby decreasing breast cancer
tumorigenesis.
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Figure 63. Model of regulation of p53 by Aurora B kinase. Mitotic kinase
Aurora B phosphorylates p53 in the DNA binding domain at four sites.
Phosphorylation of one of these sites, threonine 211, was shown to be an
important negative regulatory event for the transcriptional activity of p53. This
site, together with two others, serines 183 and 215, were also shown to be
important in the degradation of p53 via the proteasome ubiquitin pathway
resulting in reduced p53 transcriptional activity and reduced p53 mediated
apoptosis.
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The findings of this thesis are important for many reasons and have broad
implications in both understanding the mechanisms of regulation by Aurora B as
well as significant clinical relevance of Aurora B inhibition. AZD1152 was shown
to be an effective treatment in breast cancer, thus adding breast cancer to the list
of cancers evaluated for treatment with inhibitors of Aurora kinases. Mitotic
defects, polyploidy and apoptosis were confirmed in breast cancer as a result of
treatment with AZD1152, in agreement with several other reports that observed
these phenotypes in other cancer cells (Evans et al., 2008; Wilkinson et al.,
2007; Yang et al., 2007). Further, this study adds another dimension to the
inhibition of Aurora B kinase itself in that inhibition was shown to cause Aurora
B’s ubiquitination and degradation. This observation is very important to the
understanding of how AZD1152 is able to control the activity of Aurora B and
shows that it is not only doing this by competing for ATP binding but by actually
causing the degradation of the kinase and leading to decreased kinase activity.
This observation also agrees with observations for many other kinases- that the
inactive form may be unstable due to ubiquitination and degradation. Through
this mechanism, AZD1152 is likely preventing Aurora B’s auto-ubiquitination
which keeps Aurora B in the inactive form leading to its breakdown.
This study also made the important discovery that inhibition of Aurora B
led to increased p53 levels in breast cancer cells and gave the impetus for
investigation of the interaction between Aurora B and p53 (Figure 26). Indeed,
an interaction between these two proteins was found and p53 was found to be a
novel substrate for Aurora B, indicating that some mitotic regulation of p53 may
166

be occurring. This result is intriguing in the sense that p53 has never been found
to have a mitotic function, although one report described p53 at the centrosome
during mitosis but no functional mechanism was given (Tritarelli et al., 2004).
This observation is consistent with another report that p53 is a substrate of
Aurora A kinase, a known centrosome protein and mitotic regulator (Katayama et
al., 2004).

Similar to this, Aurora B is not known to have a function outside

mitosis with the exception of a report that described Aurora B in late S phase as
co-localizing with foci of phospho-HH3 in the nucleus. The role of Aurora B
during interphase was not well characterized in this study and the issue of Aurora
B function outside mitosis remains unresolved. Our data show clearly that p53
and Aurora B interact both during mitosis and during interphase (Figure 31) and
that during the mitotic interaction, p53 is located at the centromere during
prophase. We have also confirmed recently that the interaction of Aurora B and
p53 at the centromere co-localizes with Survivin (Figure 34C), another
centromere protein and member of the CPC. Our findings that Aurora B and p53
interact during late S and G2 shed some light on the subject and are interesting
clues to a possible non-mitotic role for Aurora B.
Most important and central to the findings of this thesis is that p53 was
found to be a substrate of Aurora B and adds yet another kinase to the list of
proteins that regulate the already heavily dictated p53 protein. Regulation of p53
in a positive fashion is well known by phosphorylation in the N-teminal
transactivating domain, however, our results show that p53 is phosphorylated in
the DNA binding domain and has an overall negative effect on p53 regulation. It
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was also shown that phosphorylation leads to ubiquitination of p53 by Mdm2,
reduction in oligomerization and ultimately, a decrease in p53’s transcriptional
activity.

This work focused on at least three major phosphorylation sites in p53’s
DNA binding domain: S183, T211 and S215. Of these, T211 was shown to be
most important in reducing p53’s transcriptional activity though the others may
play an important role as well since mutation of S215 was shown to nearly
completely block p53 phosphorylation by Aurora B in vitro. An alternative
interpretation of this data is that S215 may be the major Aurora B
phosphorylation site with the other sites being required for association between
the kinase and p53. The functional relevance of the regulation of p53 by Aurora
B was described by an experiment that investigated the ability of Aurora B to
block p53’s apoptotic function in the presence of DNA damage. Cisplatin was
shown to cause apoptosis in breast cancer cells at a high percentage while
introduction of Aurora B was able to reduce apoptosis effectively. This shows
that Aurora B is able to regulate one of the global functions of p53 in response to
DNA damage and is a significant new regulator of p53.

Evaluation of AZD1152 provided confirmation that this drug could be
effective in treating breast cancer as in other reported cancer types. These
findings also show that breast cancer was controlled at a similar or lower
nanomolar range. Additionally, the finding that inhibition of Aurora B caused an
increase in p53 protein level was unexpected and highly significant. This
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increase in p53 levels was due to phosphoregulation by Aurora B and is similar
to several previous reports that found that another Aurora kinase family member,
Aurora A, can also phosphorylate p53.

Phosphorylation of p53 by Aurora A has been observed at two sites in the
DNA binding domain, S315 (Blaydes et al., 2001; Katayama et al., 2004) and
S215 (Liu et al., 2004), both of which were claimed to be the more important site
for regulation of p53. These sites are located in the DNA binding domain and the
studies make the conflicting observations that phosphorylation of S315 is both a
positive and negative regulatory event for p53 transcription (Blaydes et al., 2001;
Katayama et al., 2004). Further, there is a report that S215 is the
phosphorylation site responsible for p53 negative regulation and not S315 (Liu et
al., 2004). These inconsistent observations make the picture unclear for the
phosphoregulation of p53 by Aurora A.

The observations presented in this thesis also confirm S215 as a major
phosphorylation site for p53, but do not confirm its regulatory importance. We
found that Aurora B phosphorylates this site but that there was no major impact
on p53 transcriptional activity. Instead, we found that T211, albeit a modest
phosphorylation site as far as amount, was the major site for regulation of p53
transcriptional activity (Figures 45, 54).

Our results show clearly that Aurora B and p53 are interacting in both
interphase and mitotic cells and that during mitosis, p53 is located with Aurora B
at the centromere, as confirmed by the co-localization of Survivin staining (Figure
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34C). Only one other report has shown that p53 is present at a specific locale
during mitosis and was found at the centrosome, where it is presumed to be
phosphorylated by Aurora A (Tritarelli et al., 2004). No other findings have
shown that p53 localizes to the centromere during mitosis but one report hinted
at a possible role for p53 in the spindle assembly checkpoint. Cross et al found
that the spindle assembly checkpoint in several murine models was dependent
on p53 status, as shown using p53 null MEF cells (Cross et al., 1995). These
results are in line with our finding that p53 resides at the centromere during
mitosis and points at a possible transcription independent function for p53 in
chromosome segregation.
Though it is possible that p53 does indeed have a transcription
independent function at the centromere and plays some role in the spindle
assembly checkpoint, there is an alternate view of how this data could be
interpreted. Blagosklonny describes the induction and accumulation of p53
protein during mitosis through global inhibition of transcription due to depletion of
the major negative regulators of p53 such as Mdm2, COP1 and Pirh2
(Blagosklonny, 2007) . These regulators are depleted when global transcription
is turned off during mitosis causing p53 to accumulate due to its long-lived mRNA
(Blagosklonny et al., 2002). Therefore, during mitosis p53 is still being translated
and produced from mRNA while global transcription of its negative regulators is
turned off. Following mitosis, transcription restarts and accumulated p53 can
then transactivate its target genes leading to post-mitotic arrest and apoptosis.
Given that p53 may be accumulating during mitosis and could cause the cell to
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die in G1, there is another way to explain why Aurora B may be phosphorylating
p53. It is possible that Aurora B maintains negative phosphoregulatory control of
p53 during mitosis to prevent p53 from activating a post-mitotic checkpoint and
causing cell death. Aurora B phosphorylating p53 at S183, T211 and S215 could
be reducing its ability to turn on target genes thereby bypassing cell cycle arrest
and apoptosis in G1.

Another alternate view of Aurora B phosphoregulation of p53 is that
Aurora B may be functioning in interphase to prevent p53 cell cycle arrest,
apoptosis and DNA damage inducing functions. As yet, there is no known
function for Aurora B in interphase but our data show that Aurora B is present
throughout the cell cycle, interacts with p53 during S phase and G2, and colocalizes with p53 in interphase cells. While the data presented in this study for
an Aurora B interphase function is not conclusive, the possibility remains that
cells overexpressing Aurora B could have a function to inactivate p53 outside
mitosis.

As with all studies involving chemotherapeutics, clinical relevance is a
central consideration in the design of these experiments. It was observed that
AZD1152 was effective not only in a model of primary breast cancer but also in a
model of breast cancer that was metastatic, a major complicating factor in this
disease. Tumor size was reduced by 50% in solid malignancy and metastases
were completely eliminated in treated mice versus control. Relevant to dosage,
AZD1152 was shown effective in low nanomolar ranges for all breast cancer cell
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lines treated (Figures 5, 6) and similarly, was shown effective in nearly the same
range in Skov3, PC3, Hct116, MB-MDA-435 and MiaPaCa-2 (IC50<150nM,
APPENDIX A). Of note, breast cancer cell lines were sensitive to AZD1152
regardless of Her2 status and was effective in tissue culture and the metatstatic
model of a triple negative, especially aggressive breast cancer cell line, MBMDA-231.

Important in the area of cancer treatment regimens, Yang et al found that
AZD1152 showed synergism with topoisomerase II inhibitors in leukemia cells in
vitro (Yang et al., 2007). Our results confirm a similar observation where synergy
between AZD1152 and etoposide (Vp-16) was noted over a broad range of
fractional effect in both Her18 and the parent line, MCF7 (APPENDIX D).

The effect of AZD1152 on p53 holds special clinical relevance since p53 is
lost or mutated in 50% of all cancers and because of p53’s role as the master
tumor suppressor. The use of an Aurora B inhibitor showed dramatic induction of
p53 in both tissue culture and in vivo models and should be considered as a
possible contraindication in patients with mutant p53 status.

The results reported in this thesis have covered a large amount of
territory, from the use of AZD1152 in breast cancer, to the regulation of p53 by
Aurora B. While these discoveries are significant and important, they inevitably
lead to more questions and future experiments. One example, is that we
reported that phosphorylation of p53 by Aurora B leads to p53 ubiquitination and
degradation, but the exact mechanism of how this occurs has not been
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investigated. A future study in this area should focus on determining if the
phosphorylation sites mentioned earlier (Figure 42), form a recognition motif for
Mdm2 or other E3 ubiquitination ligases to enhance their binding. Another
possibility is that the phosphorylation of p53 simply prevents p53 from binding
DNA or oligomerizing, which leads to ubiquitination since the unbound monomer
is more readily degraded. Further, examination of the p53 localization would
shed light on whether phosphorylated p53 has differential compartment
localization. For example, Aurora B phosphorylation could facilitate the shuttling
of p53 to the cytoplasm where it is subsequently degraded.
Future studies could also focus on the individual phosphorylation sites
themselves and their contribution, independent of each other, in p53’s
degradation, transcriptional activity, oligomerization or DNA binding. In this study
the triple AAA mutant of p53 was used, but with the exception of transcriptional
activity, we do not report differential effects by site. One site or a combination of
sites could serve as a code for varying effects on p53.

Important for any future consideration of the temporal interaction of Aurora
B and p53, is to determine if the most important regulation occurs during
interphase or mitosis. We show that Aurora B and p53 interact in both dividing
and non-dividing cells, but when during the cell cycle the major impact of
phosphorylation is occurring, remains an open question. Should the major
regulation be found interphase, p53 could be negatively regulated by Aurora B in
order to block the negative transcriptional effect on Cyclin B1 and Cdk2, thus
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driving the cell cycle forward. An even more interesting proposition is that p53
could have a function in mitosis. As mentioned earlier, Cross et al found that p53
was required for proper spindle assembly checkpoint and investigation of this
necessity would also be a central consideration in future experiments centering
on mitosis.

Relevant to the clinical importance of this study, future animal and human
trials involving the use of AZD1152 in p53 wild type cancers should be
investigated. Since AZD1152 has the ability to increase p53 protein level and
turn on its target genes, use of this drug could be important in turning on the
tumor killing activity of p53. Specifically, cancers that overexpress Aurora B
(Table 2) or Aurora A would be good candidates for such a trial since their
aberrant control of p53 may be contributing to the tumor phenotype without
actually having lost p53 expression. With this in mind, inhibiting Aurora B could
help to not only reduce the growth of tumor cells but could turn on the tumor
killing activity of the p53 tumor suppressor. Conversely, mutant p53 status could
aggravate the tumor phenotype and cause increased cancer growth. Careful
consideration of p53 status would be needed in any future animal or human
trials.

In summary, this study has shown that inhibition of Aurora B kinase has
significant impact on breast cancer tumorigenesis and brings to light a previously
unknown pathway for the regulation of p53 by mitotic kinase Aurora B. Further,
this study adds breast cancer to the list of cancers in which AZD1152 is shown to
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be effective via inhibition of Aurora B kinase. The data clearly show that
AZD1152 inhibits the growth of breast cancer cells regardless of Her2 status and
can cause mitotic catastrophe with subsequent apoptosis thus decreasing the
tumorigenicity of breast cancer cells. Importantly, it was also shown that
inhibition of Aurora B with AZD1152 led to ubiquitination and degradation of
Aurora B by the APC complex, an observation not previously seen with use of
Aurora B inhibitors.

With downregulation of Aurora B it was observed that p53 was induced.
This hinted at a possible direct interaction between p53 and Aurora B. Indeed, it
was found that p53 associates with Aurora B in a cell cycle dependent fashion.
Further, Aurora B was shown to phosphorylate p53 at several serine/threonine
residues in the DNA binding domain and that these events caused
downregulation of p53 levels via ubiquitination mediated by Mdm2. The
phosphorylation of one site, T211, was shown to reduce p53’s transcriptional
activity while this was not observed for phosphorylation at S183 or S215.
Functionally, Aurora B was shown to reduce p53’s capacity to mediate apoptosis
in response to the DNA damaging agent, cisplatin. Of special note, it was
observed that p53 localizes to the centromere with Aurora B and may play a role
in mitosis, especially, the spindle assembly checkpoint.

Together these data show that the mitotic kinase Aurora B is an important
target in breast cancer and an important regulator of p53 function. Consideration
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of these interactions must be given in future clinical trials which focus on Aurora
B inhibition since there is a major impact on the master tumor suppressor, p53.
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Chapter 5. APPENDICES
PPENDICES
APPENDIX A
AZD1152-HQPA
HQPA dose response curves for SKOV3, PC3, Hct116, MB-MDA-435
MB
and Miapaca-2
2 cell lines
lines.
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APPENDIX B
Cell cycle FACS analysis for Mcf7 breast cancer cells treated with 300 nM
AZD1152 for up to 48 hours.
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APPENDIX C
Colony forming and soft agar colony forming assays for MCF7 cells treated with
AZD1152-HQPA.
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APPENDIX D
Analysis of synergism between AZD1152 and etoposide (VP
(VP-16)
16) in MCF7 and
Her18 breast cancer cells.
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APPENDIX E
Cell line List
Cell Line

ATCC#

Cancer Type

Reference

MCF7

HTB-22

Breast

(Sugarman et al., 1985)

Breast

(Laronga et al., 2000)

Her18
MB-MDA-231

HTB-26

Breast

(Brinkley et al., 1980)

293T

CRL-11268

Human Embryo
Kidney

(Sena-Esteves et al., 1999)

U2OS

HTB-96

Osteosarcoma

(Heldin et al., 1986)

H1299

CRL-5803

Lung

(Giaccone et al., 1992)

Hct116

CCL-247

Colorectal

(Brattain et al., 1981)

Colorectal

(Bunz et al., 1998)

Hct116 p53-/SKOV3

HTB-77

Ovarian

(Fogh et al., 1977)

PC3

CRL-1435

Prostate

(Kaighn et al., 1979)

MIA PaCa-2

CRL-1420

Pancreatic

(Wu et al., 1977)

MB-MDA-468

HTB-132

Breast

(Brinkley et al., 1980)

MB-MDA-435

HTB-129

Melanoma

(Brinkley et al., 1980;
Chambers, 2009)

BT474

HTB-20

Breast

(Lasfargues et al., 1978)
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